

Guide

Drug Discovery & Development companies and institutes

Oss - Boxmeer - Nijmegen
The Netherlands
2022

Introduction

The region Oss - Boxmeer - Nijmegen is known to be highly active in life sciences and is home to many pharmaceutical-related companies and institutes. Together they form a complete value chain in the field of drug discovery, development, and manufacturing. Of course there are many specialised service providers too, in the areas of logistics or staffing for example. Although the players in the field of drug discovery and development are internationally active without exception, there is also a demand for local and regional collaboration between businesses, education and research institutions, hospitals, and government authorities. The campuses and Health Valley, the largest innovation network in Life Sciences & Health in the Netherlands, fulfil a crucial role in bringing the relevant parties together and profiling the region as “the place to be” in the field of life sciences. This brochure aims to clarify which players are active in the area of drug discovery and development in the Oss - Boxmeer - Nijmegen region. We provide this information to parties in the region, in other parts of the Netherlands, and abroad to show the fantastic benefits of trading, working, studying, and living here, and to make the region even stronger!

This brochure was created in cooperation with many different people and organisations. In particular, we would like to mention:

- Novio Tech Campus
- Mercator Technology & Science Park
- Pivot Park
- Gemeente Boxmeer

They enabled us to offer you a free listing in this guide.

The next update will be published in the end of 2022. Would you like to add your organisation? Do you want to make changes? Please contact us by e-mail at communicatie@healthvalley.nl

We hope you enjoy reading this brochure!



Chris Doornik,
Managing Director
Health Valley

Colophon

Contact

Health Valley
communicatie@healthvalley.nl
+ 31 (0) 85 023 0562

Editors

Team Health Valley

Next edition

Any suggestions or changes must be send to communicatie@healthvalley.nl.

Partners of this brochure



Table of contents

1. Campuses

- 1.1 Campus Heyendaal
- 1.2 Health Campus Boxmeer
- 1.3 Novio Tech Campus
- 1.4 Pivot Park

2. Research

- 2.1 Radboud University
- 2.2 Radboudumc
- 2.3 HAN BioCentre

3. Education

- 3.1 Radboud University
- 3.2 Radboudumc
- 3.3 Hogeschool van Arnhem en Nijmegen
- 3.4 Avans Hogeschool
- 3.5 ROC Rijn IJssel
- 3.6 ROC De Leijgraaf

4. Business Support

- 4.1 BOM
- 4.2 Braventure
- 4.3 Briskr
- 4.4 HAN CvVO
- 4.5 Health Valley Netherlands
- 4.6 Mercator Launch
- 4.7 Oost NL
- 4.8 Radboud Innovation Science
- 4.9 Radboudumc Valorization

5. Companies

- 5.1 3D-PharmXchange
- 5.2 Acerta Pharma BV
- 5.3 Agidens Life Sciences BV
- 5.4 Ardena (previously ChemConnection)
- 5.5 Aspen Oss
- 5.6 Avivia
- 5.7 BioAxis Research
- 5.8 Bioconnection
- 5.9 BioMed Elements
- 5.10 Byondis
- 5.11 Check-Points
- 5.12 Drug Target ID (DTID)
- 5.13 Eurofins Spinnovation Analytical
- 5.14 European Medical Contract Manufacturing (EMCM)
- 5.15 Farmaceutisch Analytisch Laboratorium Duiven
- 5.16 Future Diagnostics

p4

- 5.17 GlycoMScan BV
- 5.18 Glycostem Therapeutics
- 5.19 HCM Medical
- 5.20 Hycult Biotech
- 5.21 ImmunoPrecise Antibodies (Europe) BV
- 5.22 InProcess-LSP

p13

- 5.23 Khondrion
- 5.24 LiteVax
- 5.25 Lead Pharma
- 5.26 Luminex
- 5.27 MDxHealth

p19

- 5.28 Medimmune Pharma (Astra Zeneca)
- 5.29 Memidis Pharma
- 5.30 Mercurna
- 5.31 MSD Animal Health
- 5.32 NanoServe BV
- 5.33 NeuroDrug Research (NDR)
- 5.34 Noviocell

p27

- 5.35 NYtor
- 5.36 Osteo-Pharma
- 5.37 PharmaCytics
- 5.38 PharmSupport
- 5.39 Pivot Park Screening Centre
- 5.40 Pleco Therapeutics
- 5.41 ProtActivity
- 5.42 Protinhi Therapeutics
- 5.43 QM Diagnostics
- 5.44 qPharmetra
- 5.45 Smivet
- 5.46 SPL Medical

p39

- 5.47 Symeres
- 5.48 Synaffix
- 5.49 Synthon
- 5.50 TropiQ Health Sciences
- 5.51 Vaxxinova
- 5.52 Xenikos
- 5.53 Miscellaneous Companies

6. Hospitals

- 6.1 Bernhoven
- 6.2 Canisius Wilhelmina Ziekenhuis
- 6.3 Jeroen Bosch Ziekenhuis
- 6.4 Sint Maartenskliniek
- 6.5 Maasziekenhuis Pantein
- 6.6 Radboud university medical centre
- 6.7 Rijnstate
- 6.8 VieCuri Medisch Centrum
- 6.9 Ziekenhuis Gelderse Vallei

- p57
- p58
- p59
- p60
- p61
- p62
- p64
- p65
- p66
- p67
- p68
- p69
- p70
- p71
- p72
- p73
- p74
- p75
- p76
- p77
- p78
- p79
- p80
- p81
- p82
- p83
- p84
- p85
- p86
- p87
- p88
- p89
- p90
- p91
- p92
- p93
- p94
- p99
- p100
- p101
- p102
- p103
- p104
- p105
- p106
- p107
- p108

1 Campuses

Guide
Drugs Discovery & Development
companies and institutes

1.1 Campus Heyendaal



The place to be in Nijmegen for Drug Discovery & Development is Campus Heyendaal. In walking distance you will find Radboud University, Radboud University Medical Center, HAN University of Applied Science and Mercator Technology and Science Park with office space and support tailored to the needs R&D companies in Life Sciences, Health and High Tech. On a daily basis 50.000 students, 20.000 employees, of which 5000 academics, turn excellent science into new innovations and opportunities for society.



Address

Heyendaalseweg 141
6525 AJ Nijmegen



Telephone

+31 (0)24 361 16 53



E-mail

info@bv-campus.ru.nl



Website

www.ru.nl/bv-campus

1.2 Health Campus Boxmeer

The Health Campus Boxmeer (HCB) will become a complex of companies that are active in the field of health care or are directly affiliated with it.



High architectural requirements and mainly covered parking create a park-like environment where it is nice to work. The 25-hectare site, directly on the A-77, is a unique location. With a direct connection to the A-77, Weeze Airport can be reached within 20 minutes and Düsseldorf Airport within 50 minutes. 10 million people live in a radius of 1 hour travel. The area is ready for construction and has a zoning plan with the specific indication "care/health-related". To the north of the HCB there are also possibilities for care/health-related production companies.

The campus is like a biotope, the best breeding ground for a certain "species". The philosophy of the campus is based on the premise that bringing activities together from one specific segment has a stimulating effect. On the one hand, competition leads to more ambition, on the other hand, cooperation generates inspiration, innovation and profit. Staff and knowledge can be exchanged in the sphere of open innovation. Joint services (shared centers) can be started and the profile of the HCB is ideal for creating innovative projects and granting subsidies.

The appearance of the HCB is not strictly limited to the terrain on the A-77. Firms in Boxmeer such as Nobilon, MSD Animal Health, Nutreco and Hendrix Genetics certainly also belong to the HCB family. In a wider setting, the HCB should be considered as a partner in the network of Food Valley (Wageningen), High Tech Campus (Eindhoven), Health Valley (Nijmegen) en Pivot Park (Oss).



Address

Gemeente Boxmeer
Postbus 450
5830 AL Boxmeer



Telephone

+31 (0)485 58 59 11 (Antoine Eijkens)



E-mail

gemeente@boxmeer.nl



Website

www.sterckwijck.boxmeer.nl/bouwkavels
www.boxmeer.nl/ondernemers



Knowledge, business and innovation come together on Novio Tech Campus. Open innovation between researchers and entrepreneurs in Health and High Tech leads to growth, making the campus an innovative hotspot for products and services of a better, healthier world. From a preventive malaria-drug, to a new generation of chips. It's happening on Novio Tech Campus: Where Innovation Works.

Over the past years, Novio Tech Campus has grown strongly. The campus houses over 70 companies, from start-up to multinational, where more than 3.400 people are employed. Novio Tech Campus is the centre of Health and High Tech in the Nijmegen region. Because of the close collaboration with partners in this ecosystem, the campus is able to offer more than just office space. Entrepreneurs on our campus have access to the expertise, facilities and (inter)national networks of companies and knowledge institutions. Start-ups and young companies are provided with an integrated package of facilities and support for their enterprise.

Open Innovation is key to Novio Tech Campus. Events lead to networking and collaboration, which often results in exciting projects and initiatives. For example, during the High Tech Network Meetings, where engineers and programmers in the Nijmegen region meet and get updated on developments in High Tech. Science Meets Business gatherings put up a link between academic research and business. And the Briskr Academy provides Health and High Tech start-ups with relevant knowledge when starting up a company. These events are open to companies on and off campus.

The campus offers high end lab facilities on all ML levels, as well as shared services. For companies who want to build their own premises, there are plenty of opportunities on Novio Tech Campus. Check them out on: www.noviotechcampus.com

Services & facilities

When settling on Novio Tech Campus, you are offered a broad range of services and facilities. From entrance to worldclass events to a reception desk that is available for your questions. Novio Tech Campus offers tailor-made facilities in a close community with a dedicated team that always helps looking for solutions.

Available spaces

- Different types of laboratories (ML1-ML3 / tailor-made)
- Cleanrooms
- Pilot plants
- Office spaces

Support for your business

- Business support & coaching
- Entrance to High Tech events, eg.: High Tech Network Meeting.
- Entrance to Health events, eg.: Science Meets Business gatherings.
- Community activities, eg.: monthly Meet&Eat for all companies on campus.
- Connection with funding partners.
- Access to a Health & High Tech network, as well on campus as on an (inter)national level

Services

- Building and site management
- Reception desk (open from 08.00 - 16.30)
- Meeting rooms (from conference rooms to event halls)
- Coffee corners
- Parking lots
- Waste collection
- Security
- EHS and Arbo services
- Emergency Response Service (BHV)
- Goods and mail deliveries
- Cleaning
- Great accessibility by car and public transport (next to the Goffert railway station)

Shared equipment

Equipment in the Health and High Tech industry can often be of high cost. That's why Novio Tech Campus helps companies through offering various types of equipment:

- HPLC 1: Agilent/HP 1100
- LCMS: Agilent 1260 Infinity with 6-column changer and DAD detector, linked to 6120 Quadrupole MS (single-quad with ESI or APCI source).
- Genevac centrifugal evaporator
- Autoclave
- Fume cupboards
- Gases (natural gas, nitrogen, compressed air)•
- Industrial glassware washer
- Various glassware

If the above doesn't meet your requirements, please contact us. Together we will find a solution that fits your challenges.

www.noviotechcampus.com



Address

Novio Tech Campus
Transistorweg 7-N
6534 AT Nijmegen



E-mail

info@noviotechcampus.com



Telephone

+31 (0)6 28 87 60 81



Website

noviotechcampus.com/nl

Pivot Park is The Netherlands’ favourite campus for biopharmaceutical innovation and development of new products and therapies. Providing home to a rapidly increasing number of - successful - companies with a successful, growing campus and a close-knit community.

The companies at Pivot Park are part of a high-quality network of companies and knowledge institutes. The campus offers lab-, office- and production facilities with open access to pharmaceutical R&D facilities and expertise. Entrepreneurs at Pivot Park are optimally supported in the areas of knowledge exchange and entrepreneurship. This gives companies the opportunity to excel, grow and accelerate in the area of drug discovery and development.

The Pivot Park ecosystem consists of an active and innovative pharma R&D Community, that acts as a hub within a broader international network. The campus connects knowledge and experience between established companies, start-ups and spin-outs. Our business support regarding access to grants, private investments and venture capital will provide start-ups with all the ingredients for kick-starting their company the best way possible.

Among the almost 60 companies are start-ups and scale-ups, and also two GMP-qualified pilot plants (gram-to-kilogram and fill and finish) and an ultra High Throughput Screening Centre for the acceleration of your drug discovery. On-site analytical support (NMR and LCMS a.o.) and a well-equipped Open Access Laboratory make investments in own equipment less of a challenge.

Pivot Park is based in the heart of the city of Oss, the Netherlands, at one site with an open character. The city of Oss is surrounded by several knowledge institutions offering you access to a large pool of talented employees. Besides this Oss is perfectly accessible by car and public transport and the different international airports in its surroundings.

Life sciences culture is embedded in our site and in our community, which makes Pivot Park the hotspot for pharmaceutical innovation.

Services

What makes our park special is the fact that we have the unique means and knowledge to support drug development activities. Our highly experienced staff possesses a wealth of extensive in-depth knowledge. They provide support in a variety of areas, from maintenance and equipment of laboratories, autoclaving and washing glassware to handling complex gases, waste removal and environmental regulations.

We offer a very broad range of resources and services for companies involved in life sciences and the pharmaceutical research and development sector.

Available services at Pivot Park are a.o.:

- Building and site management
- Waste collection
- Security
- EHS and Arbo services
- Emergency Response Service (BHV)
- Goods and mail deliveries
- Cleaning
- Meeting Centre
- Restaurant
- Coffee corners
- Autoclaving and rinsing
- Utilities (Demineralised water, Compressed air, Nitrogen (gas), Vacuum, CO2)
- Liquid nitrogen

Specific lab services

- Central Cell line storage
- Cryobank (for your own cell line storage)
- Hydrogenation lab
- Quarantine lab

Equipment

A growing list with accessible equipment through the Pivot Park Community and a well-equipped Open Access Laboratory make investments in own equipment less of a challenge.

An overview:

- Agilent/Avantes UV-Vis spectrometer
- Biomek FX
- Lab Automation Workstation
- Bohle container mixer 5-10-20 L
- Bruker NIR MPA spectrometer
- Echo® 555 Liquid handler for high throughput screening
- EnVision Multilabel Plate Reader
- FACS Canto II, 3 lasers, 8 kleuren (4-2-2 configuratie)
- Flashforge Dreamer
- Flipr Tetra High-Throughput Cellular Screening System
- IncuCyte® Zoom Live-Cell Analysis System
- Malvern Sapphire NIR Imager
- MESO Quickplex SQ 120 (Meso Scale Diagnostics)
- Odyssey
- Operetta High-Content Imaging System
- PlateLoc Thermal Microplate Sealer
- Plateprep Island
- Proxima 2850
- Screening Island
- Tecan Infinite M1000
- Thorlabs Telesto II OCT
- XPeel
- X-Ray
- Zeiss Stereo Microscope



Address

Pivot Park
Kloosterstraat 9
5349 AB Oss



E-mail

info@pivotpark.com



Website

www.pivotpark.com



Telephone

+31 (0)412 84 60 10

2 Research

Guide
Drugs Discovery & Development
companies and institutes

2.1 Radboud University

Radboud University is a broad, internationally oriented research university. We value quality, combining excellent education with leading-edge research. Our academic expertise is closely related to important societal issues and contributes to applications in several sectors, including Life Sciences & Health. We play an important role in transferring knowledge to society and collaborate with regional entrepreneurs, research institutes, hospitals, public bodies and companies.

General information about research within Radboud University can be found on: www.ru.nl/english/research/radboud/profile

An overview of the top research areas within Radboud University related to Drug Discovery and Development:

- Compound synthesis, lead generation and optimization in drug discovery
- Metabolite identification and biomarker discovery
- Gene regulation
- Molecular developmental biology
- Single cell technology
- Stem cell and regenerative technology
- Neuroscience
- Immunoscience and autoimmune disease profiling
- Nanomedicine
- Microbiome
- Pharmaceutical polymorphism
- Infection and Vaccines
- Nano drug delivery and targeted drug delivery
- Data Science, Artificial Intelligence and Cyber Security
- Production- and proces optimisation
- 3R: Replacement, Reduction and Refinement of animal studies
- eHealth

Research at Radboud University is clustered in interdisciplinary thematic research institutes. The research institutes with focused activities in drug discovery and development include:

- Donders Centre for Neuroscience (DCN)
- Institute for Computing and Information Sciences (ICIS)
- Institute for Molecules and Materials (IMM)
- Radboud Institute for Molecular Life Sciences (RIMLS)

An overview of the most significant life sciences & health laboratories and research facilities within Radboud University:

- Scanning Probe Microscopy
- High Field Magnetic Laboratory (HFML)
- NMR Laboratory
- FELIX Laboratory (Free Electron Lasers for Infrared eXperiments)
- Life Science Trace Gas Facilities

More information about the labs and facilities can be found on: www.ru.nl/science/research/about-our-research/labs-facilities/

Through Radboud Research Facilities (RRF), companies, research institutes, and start-ups can use these laboratories, facilities and equipment, as well as the knowledge and expertise that is provided by Radboud University and Radboudumc. By making these high-quality equipment available for external use, company innovations can be accelerated. We are open for multiple ways of collaboration, from contract research to cooperation in subsidized projects.

More information and contact details about Radboud Research Facilities can be found on: www.ru.nl/radboudresearchfacilities/english/

For collaborating with Radboud University in drug discovery and development, please contact Radboud Innovation Science, the technology transfer office of the Faculty of Science: www.ru.nl/fnwi/onderzoek/radboud-innovation-science/contact/document/

2.2 Radboudumc

The Radboud university medical center is a leading academic center, with the mission ‘to have a significant impact on healthcare’. Examples of our impact are our renown research lines on prostate cancer, on malaria, and on the immune system, the diagnostic test for Q-fever, the surgical robot for MRI, ParkinsonNet, the diagnostic PCA3 test for prostate cancer, Food4Care, and our spin-off companies, such as Thirona and Screenpoint both focused on radiological imaging.

The R&D activities at the medical center are subdivided in 18 research themes, including:

- Cancer development and immune response
- Infectious Diseases
- Reconstructive and Regenerative Medicine
- Neurosciences and disease
- Sensory disorders
- and others


Beside the research themes, the Radboudumc technology centers are an access point for technological expertise, high-end equipment and biobanks. We can support a wealth of research questions from our own researchers, as well as external companies and institutions. Depending on the demand, the expertise of several centers can be combined to offer the best possible solution for research questions.

We have extensive experience in collaborating with industry ranging from big pharma, bio tech to start-up companies in R&D and clinical trials. We recently strengthened our collaboration with Janssen Pharmaceutica NV, Janssen-Cilag B.V. and Janssen Vaccines & Prevention B.V to bring high quality innovative academic research faster to the patient, we concluded a partnership with Viiv Healthcare for identification of novel targets in HIV and we entered into a collaboration with Imec and Wageningen University for OnePlanet.

General information about research within the Radboudumc can be found on: www.radboudumc.nl/en/research

Research institutes and themes

Radboud institute for Health Sciences		Healthcare improvement science	Donders Center for Medical Neuroscience
Cancer development and immune defense	Infectious diseases and global health	Alzheimer's disease	
Rare cancers	Inflammatory diseases	Disorders of movement	
Tumors of the digestive tract	Mitochondrial diseases	Neurodevelopmental disorders	
Urological cancers	Reconstructive and regenerative medicine	Sensory disorders	
Women's cancers	Renal disorders	Stress-related disorders	
	Vascular damage		
Nanomedicine			
Radboud institute for Molecular Life Sciences			



The HAN BioCentre is the Centre of Expertise for Biotechnology and Analysis at HAN University of Applied Sciences in Nijmegen.

Our researchers conduct applied research in the biosciences & chemistry, working with students and our industrial partners, to answer the question of how we can live in the responsible environment and make smart use of nature. We provide applied research within the whole biodiscovery chain: from discovery through analysis, to production and application of (new) biomolecules. The resulting knowledge contributes to the biobased economy, drug discovery and bio-informatics|data science domains. Examples include the production of alternative raw materials for industry based on fermentation technology, developing separation methods to allow for full use of side-streams from agriculture and horticulture, explore the possibilities for new medicines from plants, the development of alternative test methods to replace animal experimentation and designing methods and software to better utilise the enormous amount of (genetic) data.

We work closely with companies that are also committed to the same ambition. We train students in a multidisciplinary environment to contribute to solving social issues from different perspectives. Our expertise ranges from analytical and medicinal chemistry to microbiology and fermentation technology, including biochemistry, cell biology, molecular biology and physiology as well as bioinformatics and data science.

Services and Products

- Contract research
- Cooperative research
- Facility sharing
- Tailor made courses: fermentation technology, downstream processing, introduction to mass spectrometry, proteomics, applied microbial genomics and plant tissue culturing techniques.

Facilities

- Lc-ESI-Ion Trap MS (Liquid Chromatography-Mass Spectrometry)
- Confocal laser microscope
- Scanning electron microscope
- Bioreactors ranging between 1 and 20 litres
- Cell disrupter homogenizer
- Various filtration units
- FPLC systems (Fast Protein Liquid Chromatography)
- GC for fatty acid analysis
- qPCR and PCR systems
- Freeze dryer
- Fluorescence microscope
- Multiplate reader
- Various HPLC systems with UV, DAD, fluorescence and ELSD detection
- Several GC systems with FID detection
- GC-MS
- Headspace-GC-MS
- DSC (Differential Scanning Calorimetry)
- IR spectroscopy (Infra Red Spectroscopy)



Address

Laan van Scheut 2
6525 EM Nijmegen



Telephone

+31 (0)24 353 19 00



E-mail

info@hanbiocentre.nl



Website

specials.han.nl/sites/biocentre-en/



Number of persons employed

14

Area of activity

- Product development
 - Drug development
 - Diagnostics
- Contract Research Organisation
- Supporting Pharma Service

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Biomarkers / Translational Sciences

Area of work

We work in multidisciplinary teams combining bio-informatics, molecular biology, fermentation technology, biochemistry and analytical chemistry. We work on various research themes:

- Antimicrobial activity
- *C. elegans* screening system
- Microbial oil production
- Gene expression
- Biorefinery

3 Education

Guide
Drugs Discovery & Development
companies and institutes

Location: Nijmegen

Bachelors

- www.ru.nl/opleidingen/bachelor/biology/
- www.ru.nl/opleidingen/bachelor/molecular-life-sciences/
- www.ru.nl/opleidingen/bachelor/science/
- www.ru.nl/opleidingen/bachelor/chemistry/

Masters and Master Specialisations

- www.ru.nl/opleidingen/master/medical-biology/
- www.ru.nl/english/education/masters/medical-epigenomics/
- www.ru.nl/english/education/masters/human-biology/
- www.ru.nl/english/education/masters/neurobiology/
- www.ru.nl/opleidingen/master/molecular-life-sciences/
- www.ru.nl/english/education/masters/chemistry-of-life/
- www.ru.nl/opleidingen/master/chemistry/
- www.ru.nl/english/education/masters/physical-chemistry/
- www.ru.nl/english/education/masters/molecular-chemistry/
- www.ru.nl/english/education/masters/science/
- www.ru.nl/english/education/masters/medical-epigenomics/
- www.ru.nl/english/education/masters/physical-chemistry/
- www.ru.nl/english/education/masters/neurobiology/
- www.ru.nl/english/education/masters/molecular-chemistry/



Address

Faculteit der Natuurwetenschappen,
Wiskunde en Informatica
(Huygensgebouw/Linnaeusgebouw)
Heyendaalseweg 135
6525 AJ Nijmegen



Telephone

+31 (0)24 365 33 42



Website

www.ru.nl/fnwi

Location: Nijmegen

Bachelors

- www.ru.nl/studiegids/fmw/bachelor/geneeskunde/algemene-informatie/
- www.ru.nl/studiegids/fmw/bachelor/biomedische-wetenschappen/voorwoord/

Masters and Master Specialisations

- www.ru.nl/studiegids/fmw/master/geneeskunde/algemene-informatie/
- www.ru.nl/prospectus/fmw/master/biomedical-sciences/preface/
- www.ru.nl/prospectus/fmw/master/molecular-mechanisms-disease/preface/



Address

Radboudumc /
Faculteit der Medische Wetenschappen
Geert Grooteplein 10
6525 GA Nijmegen



Telephone

+31 (0)24 361 11 11



Website

www.radboudumc.nl

3.3 Hogeschool van Arnhem en Nijmegen



Location: Nijmegen
Academie Toegepaste Biowetenschappen en Chemie

Bachelor Chemie
www.han.nl/chemie

Bio-informatica
www.han.nl/bio-informatica


Bachelor Biologie en Medisch Laboratoriumonderzoek
www.han.nl/bml

Bachelor Chemie deeltijd
www.han.nl/chemie-dt

Bachelor Life Sciences
www.han.nl/life-sciences

Bachelor Chemistry
www.han.nl/chemistry

Master Molecular Life Sciences
www.han.nl/mmls

 **Address**
Laan van Scheut 2
6525 EM Nijmegen

Ruitenberglaan 31
6826 CC Arnhem

 **Telephone**
+31 (0)24 353 19 00


 **Website**
www.han.nl




3.4 Avans Hogeschool

Location: 's-Hertogenbosch

- www.avans.nl/opleidingen/opleidingzoeker/chemie-s-hertogenbosch-voltijd-bachelor/introductie

 **Address**
Onderwijsboulevard 215
5223 DJ 's-Hertogenbosch


 **Telephone**
+31 (0)88 525 75 50


 **Website**
www.avans.nl



Locations: Arnhem, Nijmegen

- www.rijnijssel.nl/mbo-opleidingen/techniek/#!/subcategorie=4

 **Telephone**
+31 (0)26 312 90 00


 **E-mail**
info@rijnijssel.nl


 **Website**
www.rijnijssel.nl



Locations: Oss, Cuijk

- www.leijgraaf.nl/opleidingen/opleidingen/techniek-samenleving/laboratoriumtechniek/

 **Address**
Postbus 420
5460 AK Veghel

 **Telephone**
+31 (0)88 017 00 00

 **E-mail**
info@leijgraaf.nl

 **Website**
www.leijgraaf.nl

4 Business Support

Guide
Drugs Discovery & Development
companies and institutes



The Brabant Development Agency (BOM) is a growth accelerator. We work together with innovative entrepreneurs and with people who can solve social issues. We help to make dreams come true, to access new markets and turn groundbreaking concepts into tangible products and services.

Together we work to make our cast-iron competitive position more sustainable and to further increase it. That's because Brabant has everything it takes to perform at a global level, whether in terms of our economic position, our technological knowhow, and our society.


Our focus
We work together with businesses that embrace new developments and who understand that they can achieve more by partnering with other pioneers in Brabant's corporate world, our knowledge institutes, and an incentivizing government. By encouraging activities that anticipate the fourth industrial revolution, we are creating the economy of tomorrow. We create an appealing climate for foreign businesses and for retaining employment levels. We aid Brabant companies that want to spread their wings abroad and we stimulate the development of sustainable energy products.


Our strength
BOM is a public company that builds bridges between entrepreneurs, knowledge institutes, and the authorities. We have no commercial interests, and our independent position opens doors that often stay closed to commercial ventures. In this manner we encourage cooperation and bring people and resources together. BOM will often supply capital using the funds that we manage and the financial opportunities that arise from our networks. Through our Investor Readiness Program, we prepare startups to apply for funding. That's because when BOM is on board confidence is raised, which can only be good for acquiring further capital and for the growth of your company.

Do you need network, collaboration, knowledge, insights, money, market entrance, business development support or anything else? Please let us know, and we will do everything what is in our power to come up with a solution for you!

 **Address**
Goirlese Weg 15
5026 PB Tilburg

 **Telephone**
+31 (0)6 52 60 71 87

 **E-mail**
rhein@bom.nl (program manager Life Sciences)


 **Website**
www.bom.nl




Every promising startup deserves to be successful. As the entrepreneur you are in control but you don't have to do it all by yourself. Braventure offers quick access to knowledge, community, facilities and capital with only one goal: to speed up your startup and make it successful.

Partners of Braventure are BOM, BIM, Avans, Midpoint Brabant, Rewin, Tilburg University, HAS, Brainport Development, TU/e, AgroFood Capital, Breda University.

More information on www.braventure.nl

 **Address**
Burg. Brokxlaan 12
Gebouw 88
5041 SB Tilburg

 **E-mail**
info@braventure.nl

 **Website**
www.braventure.nl

4.3 Briskr



Innovation is key to economic growth and the creation of employment. Start-ups, scale-ups and grown-ups encounter many challenges in their road to successful growth. Briskr is a consortium of organizations that support entrepreneurs in Health and High Tech (H&HT) who are facing these challenges.

Briskr is the program that helps startups and SME's to grow faster and make a bigger impact on Health and High Tech. Companies in these sectors encounter a lot of challenges in their road to successful growth. We support entrepreneurs in facing these challenges.


Briskr believes that interaction between knowledge-intensive companies, knowledge institutions like universities and governmental institutions is essential to realize innovation. This interaction is even more important in the top sectors Life Science & Health, High Tech Systems and Materials and Chemistry or any cross-over between these sectors.


That's why Briskr offers a specific set of tools to entrepreneurs in the above sectors.


- Scouting and screening of new and promising companies. Often during events like the Science Meets Business gatherings.
- Once a company has been scouted, its questions and challenges are presented to the Briskr partners. Together they ensure that the business receives 'tailor-made' support.
- The Briskr Academy offers workshops and events on various themes, from Intellectual Property (IP) to privacy regulations for SMEs.

The Briskr consortium is formed by the most important partners in the field of support for the Health and High Tech sectors. The involved parties are: Business Cluster Semiconductors (BCSEMI NL), Municipality of Nijmegen, Health Valley Netherlands, Kadans Science Partner, Novio Tech Campus, East Netherlands Development Agency (Oost NL), Province of Gelderland, Radboud University, Radboudumc and SMB Life Sciences.

In addition to the core partners, associate partners strengthen the network. Business Cluster Semiconductors, Rabobank Rijk van Nijmegen and The Economic Board are the first associate partners and will be followed by others shortly.

 **Address**
Novio Tech Campus
Transistorweg 7
6534 AT Nijmegen

 **Telephone**
+31 (0)24 204 90 61

 **E-mail**
info@briskr.eu

 **Website**
briskr.eu



4.4 HAN CvVO

The Centre of Entrepreneurship (CoE) is a central department of the HAN University of applied sciences (Hogeschool van Arnhem en Nijmegen). The HAN has about 35.000 bachelor students in several disciplines. There are about 40 research groups. Health is one of the three strategic areas of the HAN. The HAN also offers master programs and post university training facilities.

Targets groups of the CoE are students, alumni and other persons and organizations who are interested in entrepreneurship. This CoE is also active in regional and (inter-)national projects to stimulate entrepreneurship, startups and innovation.

- The HAN and the Centre of Entrepreneurship offers the following services for SME's and entrepreneurs:
- Courses in entrepreneurship
 - Entrepreneurship events
 - Finance for early stage startups
 - Networks
 - Individual support for (student-)entrepreneurs
 - Projects to stimulate entrepreneurship
 - Links to students for internships and practical training
 - Connections to research facilities and researchers
 - Graduation / internship in your own company
 - Student entrepreneur agreement (to combine study and business).

- The Centre of Entrepreneurship of the HAN works together with:
- The Mercator Launch (Radboud University, UMC, HAN)
 - Startup Fonds Gelderland (finance for start-ups)
 - ORION, 10 partners (universities and regional organizations) project to support startups
 - Startup Nijmegen (facilities and support for entrepreneurs)
 - Startup Delta and Startup Gelderland
 - Start Club Arnhem (Businessclub for start-ups in Arnhem)
 - Startlife (Food-Agri) and Briskr (Health, E-Health and Tech) for supporting startups in the region. ORION focuses on the other sectors (Energy, Creative industries, ICT, cross overs, etc.)
 - Local, regional and national governmental organizations to stimulate entrepreneurship
 - Health Valley, Food Valley, Kiemt (Energy)
 - Oost NL (regional economic development organization) and The Economic Board.
 - Incubators (IPKW Arnhem, Novio Tech Campus Nijmegen, Mercator etc.)
 - National researchers on entrepreneurship and family business.

 **Address**
Ruitenberglaan 26
6826 CC Arnhem

 **Telephone**
+31 (0)6 29 02 30 30 (Karel Rietdijk)

 **E-mail**
cvo@han.nl

 **Website**
www.han.nl/cvo

 **Number of persons employed**
14

4.5 Health Valley Netherlands



Strengthening the power of innovation

Health Valley Netherlands is the biggest Life Sciences & Health innovation network in the Netherlands. The network unites companies, care organisations, knowledge institutes and authorities, and enables them to grow stronger together. Whether we're providing developers with care needs and requirements or delivering innovations to the patient: we bring technology to the care sector, together. Real innovative power develops where the needs of the care sector are integrated into relevant knowledge and expertise, resulting in technological innovations, new medicines or devices, and other methods of working. Through a combination of innovative, market and entrepreneurial strength, our partners give an unmistakable boost to the care sector and also encourage economic growth.

As the Netherlands' largest innovation network in Life Sciences and Health, we have dedicated ourselves to making a difference for more than ten years. We are based in the eastern Netherlands, with locations in Nijmegen and Enschede, but our work reaches across the Netherlands and even beyond its borders through our collaborations with many national and international partners. We are always strengthening our position at both the domestic and global levels.

Based in The Netherlands?

Innovation network Health Valley primarily boosts the innovation capability of companies and care providers based in The Netherlands. If your company is based in The Netherlands and active in the field of Life Sciences & Health, becoming a partner of our network may be beneficial to help you reach your national or international goals.

Address
Novio Tech Campus
Transistorweg 7R
6534AT Nijmegen

Telephone
+ 31 (0)85 023 0562

Planning to base your company in The Netherlands?

Health Valley partners with Oost NL to support international companies active in the field of Life Sciences & Health in the eastern Netherlands. Oost NL assists foreign companies wishing to establish their businesses in the eastern Netherlands with locations, expansion, and relocation services, free of charge.

Do you want to realise innovative ideas through a public-private partnership?

Health Valley assists partners to realise innovative projects by bringing together knowledge institutes, companies, and healthcare organisations. For this purpose we are open to cooperating with other cluster organisations in Life Sciences & Health.

For international companies from outside the European Union

If you are an entrepreneur or company (from outside the European Union) thinking of establishing your business in The Netherlands, please find information to facilitator services [here](#).

E-mail
info@healthvalley.nl

Website
www.healthvalley.nl




4.6 Mercator Launch

Mercator Launch is a pre-incubation platform founded by the Radboud University together with partner Radboudumc & HAN and offers a 12 week IMPROVE program to early phase entrepreneurs at the Heyendaal Campus.

The program is created to support students, researchers and alumni in the difficult phase from academic environment to incubation and focuses on validation of their ideas. Besides the Improve program Mercator Launch also boosts awareness on entrepreneurship and entrepreneurial skills at the Heyendaal campus. Finally, the program connects ideas and entrepreneurs with the regional and national start-up ecosystem and provides showcases of innovative start-ups that emerge from these partnering knowledge institutions.

You can find Mercator Launch at the Mercator Science and Technology Park and you can turn to Mercator Launch for:

- Inspiring and informative workshops and events
- 1-on-1 coaching & business support
- Workplaces
- R&D facilities
- Funding
- Network, Field Experts, Interesting contacts, such as Business Developers, Investors, fund managers, accountants, lawyers, potential clients etc.



Address
Toernooiveld 100
6525 EC Nijmegen

Telephone
+31 (0)24 362 00 60

E-mail
hello@mercatorlaunch.nl

Website
www.mercatorlaunch.nl

4.7 Oost NL



We offer companies a ‘soft landing’ in East Netherlands.

Oost NL (East Netherlands Development Agency) focuses its activities and projects on strengthening and stimulating the economy of the provinces of Gelderland and Overijssel, the Netherlands. We work with regional businesses and are commissioned by the Ministry of Economic Affairs and Climate Policy and the respective provinces.

Oost NL plays an important role in executing the economic policies of the Dutch government and the provinces of Gelderland and Overijssel and its various city governments. To achieve this it is necessary to encourage a close cooperation between businesses, regional institutes, knowledge institutes, and intermediaries. Oost NL acts as a bridge between government, companies and knowledge institutes.

In line with the government’s ‘top sector policy’, we focus on areas such as the top sector Life Sciences & Health, including Drug Discovery & Development. A team of specialists aids businesses in this sector, through our three main activities:

Innovation

We support the regional business environment by helping city governments and SMEs to bring innovations to market. This is done with knowledge, access to funding (including European-wide funds), networking and one-on-one contacts. The results: fundable business cases (usually focused on market introductions), innovation projects and programs, open innovation centers and establishing campuses.


Investments

We invest in starting and growth-phase SMEs. We do this partly with risk capital from various revolving innovation funds, and partly through our knowledge, networks and personal contacts. Through the revolving funds we provide for direct as well as indirect investment and take care of the fund management. In addition, we stimulate and support public and private investors. The result: growth through financing.

Internationalization


We offer companies from outside the Netherlands, as well as from other regions of the country, a ‘soft landing’ in East Netherlands. Through us, international companies gain access to our regional networks as well as assistance with trade promotion. We help owners of SME’s from East Netherlands to internationalize through matchmaking via our worldwide network of partners.

 **Address**
Laan van Malkenschoten 40
7333 NP Apeldoorn

 **Telephone**
+31 (0)88 667 01 00

 **E-mail**
info@oostnl.nl

 **Website**
oostnl.com

 **Contactperson**
Susan van Bortel (team manager Health & Food)
susan.vanbortel@oostnl.nl
+316 1841 6745


4.8 Radboud Innovation Science


Radboud Innovation Science (RIS) is the valorisation & innovation department of the Faculty of Science of Radboud University, offering grant support, project coordination and knowledge transfer. RIS is the first point of contact for collaborations in Drug Discovery & Development at Radboud University and closely cooperates with the valorisation department of Radboudumc.

Our services include:

- **Partnerships and Cooperation:** We arrange partnerships with companies, governments and knowledge institutes.
- **Grant Support:** We support our scientist with the acquisition of research funding.
- **Contract Research:** We offer knowledge and equipment to companies.
- **Business Development:** We offer assistance in protecting scientific knowledge (Intellectual Property) and technology transfer (Licensing).
- **Spin-offs:** We scout ideas and help with the creation and funding of spin-offs.
- **Project Coordination:** We help with the establishment and maintenance of consortia and carry out financial and administrative project coordination.

Do you have questions or wish to explore a collaboration Radboud University in Drug Discovery & Development, please do not hesitate to contact us.

 **Address**
Huygens Building
Heyendaalseweg 135
6525 AJ Nijmegen

 **Telephone**
+31 (0)24 365 22 29

 **E-mail**
radboudinnovation@science.ru.nl

 **Website**
www.ru.nl/science/research/
radboud-innovation-science/


Through collaborative research, clinical studies, shared facilities, intellectual property protection, licensing, and spin-off businesses, the medical center aims to have a significant impact on healthcare.


Examples of our impact are our renown research lines on prostate cancer, on malaria, and on the immune system, the diagnostic test for Q-fever, the surgical robot for MRI, ParkinsonNet, the diagnostic SelectMDx test for prostate cancer, and our spin-off companies, such as Thirona and Screenpoint. We have extensive experience in collaborating with industry ranging from big pharma, bio tech to start-up companies in R&D and clinical trials. Annually, our department evaluates over 1,400 contracts and 14 invention disclosures, and supports the founding of 3 spin-off companies.

Business Development
Besides stimulating and negotiating research collaborations, we support the creation of spin-off companies with technologies from Radboudumc by

evaluating business plans, protecting IP rights, negotiating license agreements, searching for initial funding and initiating contact with candidate-CEOs and other experts. We recently strengthened our collaboration with Janssen Pharmaceutica NV, Janssen-Cilag B.V. and Janssen Vaccines & Prevention B.V. to bring high quality innovative academic research faster to the patient and we concluded a partnership with Viiv Healthcare for identification of novel targets in HIV.

Grant Support Office
We support researchers and entrepreneurs at Radboudumc in acquiring funding from national and international sources. Our team also coordinates complex grant projects and is the initial contact point for funding bodies and companies.

 **Address**
Reinier Postlaan 2
6525 GC Nijmegen

 **Telephone**
+31 (0)24 361 89 37

 **E-mail**
secretariaat.val@radboudumc.nl

 **Website**
www.radboudumc.nl/en/research/valorization

5 Companies

Guide
Drugs Discovery & Development
companies and institutes

5.1 3D-PharmXchange



3D-PharmXchange is a Dutch consultancy firm specialized in development of pharmaceuticals and diagnostics.

Our goal is to speed up your development program. To do so we bring direct solutions that fit your company on the dimension of time, cost and risk. Through our long-standing experience we know how to take your development program seamlessly to the next level. Even for complex multidisciplinary projects and in a wide range of disease areas.

- Services and Products**
What services does your company offer?
- Consultancy services regarding research & development processes

- Expertise or Knowledge**
- Clinical
 - Non-clinical
 - CMC
 - Regulatory affairs
 - Project management

Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)13 534 82 72

E-mail
info@3d-pxc.com

Website
www.3d-pxc.com

Number of persons employed
16

- Area of activity**
- Product development
 - Drug development
 - Supporting Pharma Service
- Drug Discovery and Development activities pursued**
- Biomarkers / Translational Sciences
 - Pre-clinical development Safety and toxicology
 - Clinical development phase I/II
 - Regulatory
- Area of work (indications)**
3D-PharmXchange is a Dutch consultancy firm specialized in development of pharmaceuticals and diagnostics.



5.2 Acerta Pharma BV

Acerta Pharma, a member of the AstraZeneca Group, is creating novel selective therapies intended for the treatment of autoimmune diseases and cancer.

AstraZeneca acquired a majority stake interest in Acerta Pharma, which serves as AstraZeneca’s haematology-oncology research and development centre of excellence. Leveraging its strength in oncology, AstraZeneca has established haematology as one of four key oncology disease areas of focus. Acerta holds offices in Oss and Den Hague in the Netherlands, and in San Carlos and San Francisco in the USA. For more information, please visit www.acerta-pharma.com.

Acalabrutinib is Acerta’s lead program which was developed based on Acerta’s discovery efforts. It is an investigational covalent Bruton tyrosine kinase (BTK) inhibitor currently under investigation in multiple Phase 3 clinical trials. The clinical program includes over 20 trials in hematologic malignancies and solid tumors. Over 1,800 patients have participated in these trials to date.

Calquence (acalabrutinib) was granted accelerated approval by the US Food and Drug Administration (FDA) in October 2017 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Acerta Pharma takes an innovative approach to the discovery and development of novel low molecular weight.

- Services and Products**
What products does your company make?
- Acalabrutinib
- Expertise or Knowledge**
- R&D expertise in the area of discovering and developing novel low molecular drugs for the intended treatment of haematological indications in oncology

Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)412 70 05 74

E-mail
info@acerta-pharma.com

Website
www.acerta-pharma.com

Number of persons employed
40

Area of activity

- Product development
 - Drug development
- Supporting Pharma Service

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Biomarkers/ Translational Sciences
- Clinical development phase I/II
- Clinical development phase III/ Registration
- Regulatory

Area of work (indications)
Haematology & Oncology



Progress brings us together.

Agidens is an international player in the Life Sciences industry. An industry where patient safety is a must, and for Agidens a promise. In co-creation with our customers we design, build, automate, commission, validate and maintain highly efficient pharmaceutical processing solutions. We help our customers to improve their processes and manage their assets. We provide support to assure full compliance with current regulations. Our unique combination of turnkey engineering projects, process knowledge, automation solutions and validation & compliance competencies, makes us an ideal partner. We love the most challenging projects to improve efficiency, quality, safety and reliability. Our expertise covers the pharmaceutical industry, laboratories, hospitals, medical devices, biotechnology, blood and tissue banks, cosmetics and API.

Services and Products


- What services does your company offer?
- Consulting & Engineering
 - Validation & Compliance
 - Process solutions & Automation
 - Maintenance & Service support


What products does your company make?

- AFITT, automated integrity tester for multiple sterile filters.
- Skids (e.g. CIP/SIP)
- Formulation systems

Expertise or Knowledge


- GxP Compliance
- Qualification, Commissioning and Validation
- Computerised System Validation
- Formulation systems
- CIP/SIP (Cleaning & Sterilization In Place)
- Pharmaceutical equipment
- Monitoring systems
- Manufacturing Execution Systems (MES)
- Industrial automation and system integration (PLC/SCADA/MES)
- Laboratory Equipment Managed Services
- Thermal Validation Services

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 183 64 33 44

 **E-mail**
info@agidens.com

 **Website**
www.agidens.nl

 **Number of persons employed**
650 (worldwide)

Area of activity

- Supporting pharma service

Area of work (indications)

- Consulting & Engineering
- Validation & Compliance
- Process solutions & Automation
- Asset Management & Maintenance & Service support



Ardena is your reliable partner to navigate your small molecule through drug development into the clinic.

We offer an integrated services platform to reduce the timeline from initial idea to first-in-human (FIH) clinical verification. The Ardena services platform includes make, analyse and file capabilities and capacities that will reduce the complexity and risks of Phase 1 timelines. We integrate drug substance chemical synthesis capabilities with drug product formulation expertise, supported by industry leading solid state research competencies.

Ardena offers dedicated state-of-art nanomedicine development, analysis and process capabilities. Our regulatory CMC experts are well versed in the informational requirements, submission formats, and approval processes of various authorities. Operating 6 sites across 4 countries, Ardena provides also global clinical supply services, covering management of clinical supplies, kitting, primary and secondary packaging.


Ardena is uniquely positioned to meet bioanalytical needs offering quantitative bioanalysis in all phases of pharmaceutical development, qualitative and semi-quantitative analysis for metabolism studies, in-house method development and validation according to international regulatory guidelines.


Services and Products


- What services does your company offer?
- Drug substance process and analytical development
 - Drug substance manufacture
 - Nanomedicine process and analytical development
 - Nanomedicine manufacture
 - Solid state research
 - Drug product process and analytical development
 - Drug product manufacture
 - Packaging, labelling, and clinical logistics
 - Bioanalytical services
 - Dossier development services

Expertise or Knowledge


- Chemical pharmaceutical development
- Dossier centric development
- Nanomedicine development
- Solid state research
- Bioanalysis

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 (0)412 84 60 24

 **E-mail**
info@ardena.com

 **Website**
www.ardena.com

 **Number of persons employed**
Ardena Oss: 91
Ardena Amsterdam: 12
Ardena Assen: 73
Ardena total: 300

Area of activity

- Contract Research Organisation
- Contract Manufacturing Organisation
- Supporting pharma service

5.5 Aspen Oss



Aspen Oss has a proud history in the production of APIs spanning over almost 100 years. We specialize in the production of complex, highly potent APIs (HPAPIs). We work from a deeply rooted and pro-active quality culture.

Our facilities are successfully inspected and approved by governmental authorities such as the US FDA, EMA, PMDA.

We offer our customers a true partnership by consistently delivering high product quality on schedule. Aspen Oss provides you extensive support at all stages of your project: from proof of concept forward through registration and commercialization.

Services and Products

- What services does your company offer?
- Production of chemical, biochemical API's and Peptides and extensive regulatory services.

What products does your company make?
Our APIs are used in among others the following therapeutic areas:

- Women's health
- Male health
- Drug and alcohol dependency
- Muscle relaxation
- Oncology
- Central nervous system
- Anticoagulant
- Veterinary applications

Expertise or Knowledge

- Almost 100 years strong in handling HPAPIs and complex chemical reactions
- A deeply rooted and pro-active quality culture
- We understand your regulatory requirements
- We value the protection of our employees, the environment and our products



Address
Kloosterstraat 6
5349 AB Oss

Telephone
+31 (0)88 277 90 00

E-mail
api@nl.aspenpharma.com

Website
www.aspenoss.com

Number of persons employed
850



5.6 Avivia

Avivia is a Dutch independent specialized pharmaceutical development company engaged in CRO service activities, drug repositioning, repurposing and (re) formulation.

Our expertise and capabilities are centred around the development of value-added generic drugs, life cycle management of branded drug products, complex formulations and CMC development of new drug products (NCE).

We operate a hybrid business model combining CRO service activities (both full development programs as well as stand-alone services) with internal product programs aimed at the development of value-added products.

Services

- What services does your company offer?
- We provide full analytical and pharmaceutical product development services and strategic advice to formulate the Target Product Profile

Expertise or Knowledge

- Hands-on experience in pharmaceutical and analytical drug product development
- State-of-the-art analytical and pharmaceutical lab facilities
- Innovation leading to creation of novel Intellectual Property
- Competitive Intelligence to establish proper Target Product Profiles

Address
Novio Tech Campus
Transistorweg 5 (Building M)
6534 AT Nijmegen

Telephone
+31 (0)6 19 68 67 32

E-mail
info@avivia.nl

Website
www.avivia.nl

Area of activity

- Product development
- Contract Research Organisation

Drug Discovery and Development activities pursued

- Pre-clinical development DMPK
- Clinical development phase I/II
- Clinical development phase III / Registration
- Regulatory
- Commercial and marketing

Area of work (indications)

Not limited to a particular area

Number of persons employed
8-12

5.7 BioAxis Research



BioAxis Research specializes in Computational Medicinal chemistry and Drug Design.

Our expertise ranges from Compound Library Design (hit/lead/druglike, focussed, complementary or diverse), Hit Discovery via in silico screening, Lead Optimisation encompassing ligand-based (calculated properties, SAR approaches, Deep Learning classification strategies), protein structure-based (flexible docking, binding site analyses and analogue generation, scaffold hopping and in-site modelling of structural modification, through prediction of ADMET properties.

BioAxis Research works with Commercial organisations in Europe and the USA, from small biotech start-ups to large Pharma companies. Collaboration with compound suppliers, major European screening centres and academic groups also takes place. Our work involves the use of both commercial modelling software and Open Source solutions where appropriate.

- Services and Products**
What services does your company offer?
- Collaborative research to identify leads and develop drug candidates
 - Cheminformatics, molecular property calculations, data mining
 - Structure, Fragment-based drug design, Computational Medicinal Chemistry
 - Combined data, text and network mining, association analyses
- Expertise or Knowledge**
- Compound collection analyses and library design
 - Structure-activity relationships
 - Multiparameter compound optimization
 - Compound progressibility analyses

Address
Pivot Park Oss
Industrielaan 63
5349 AE Oss

Telephone
+31 (0)6 53 58 91 56

E-mail
contact@bioaxisresearch.com

Website
www.bioaxisresearch.com

Number of persons employed
1

- Area of activity**
- Contract Research Organisation
 - Supporting pharma service
- Drug Discovery and Development activities pursued**
- Target selection and validation
 - Hit identification
 - Lead finding
- Area of work (indications)**
Early research in variety of indications

5.8 Bioconnection




BioConnection offers young and innovative biopharmaceutical companies access to our state-of-the-art-GMP manufacturing facility and a broad range of support services.

We are a contract services and manufacturing organization for the development and manufacture (Filling and Freeze drying) of injectable (bio)pharmaceutical products. The Netherlands are located centrally in Europe and from our proprietary site in Oss we supply both clinical as commercial products to our worldwide customers (FDA/EMA). Besides the central location, The Netherlands are also well known for their professional flexibility, organizational savvy and command of foreign languages. Besides our own EMA/FDA approved facility we have access to various facilities across Europe to enable an unmatched flexibility in solutions, capacity and capability. The cornerstones of our CMC services are: Drug Product development, Fill and Finish, Freeze drying and Finished Product services.

- Expertise or Knowledge**
- Fill&Finish and Freeze-dry
 - Clinical trial material
 - Commercial/marketed product manufacturing
 - Process transfer and validation
 - Process development

Services and Products



Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)412 63 79 37

E-mail
info@bioconnection.eu

Website
www.bioconnection.eu

Number of persons employed
40

Area of activity

- Product Development
- Contract Manufacturing Organisation

5.9 BioMed Elements



BioMed Elements strives to develop biomaterials that will enhance lives.

We focus on biomaterials based on biocompatible and degradable biopolymers. BioMed Elements develops, manufactures and supplies biomaterials for application areas such as wound management, medical aesthetics, orthopedics, tissue engineering and cosmetics.

The BioMed specialists have extensive expertise and knowledge of biopolymer chemistry and medical devices. Our in-house R&D team is capable of processing these natural materials into various functional end forms. These functional forms can be sponges, sheets, powders, sprays and gels.

Services and Products

- What services does your company offer?
- Drug delivery development
- What products does your company make?
- Biopolymer based materials for pharmaceutical application

Expertise or Knowledge

- Biopolymers and biologics
- Flow chemistry; developing delivery applications
- Biocompatibility

Address
Kerkenbos 1077V
6546 BB Nijmegen

Telephone
+31 (0)24 711 40 29

E-mail
info@biomed-elements.com

Website
www.biomed-elements.com

Number of persons employed
5-9

Area of activity

- Product development
 - Medical technology
- Contract Research Organisation

Drug Discovery and Development activities pursued

- Clinical development phase I/II

Area of work (indications)

- Delivery mechanism
- Release profile

5.10 Byondis



Driven to improve patients' lives, Byondis is a privately held, science-based, clinical stage biopharmaceutical company driven by our purpose: providing novel treatments with an improved therapeutic window for patients with a high unmet medical need.



Byondis employs current insights in tumor biology and immunology to select new molecular targets and design new mechanisms for new biological entities (NBEs), such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). Byondis uses its proprietary molecular concepts ByonZine®, a duocarmazine linker-drug (LD) technology and ByonShieLD®, a site-specific conjugation technology, to generate next generation ADCs.

Byondis' broad R&D portfolio, targeting intractable cancers and autoimmune diseases, comprises preclinical as well as early- and late-stage clinical development programs, including the anti-HER2 ADC [vic-] trastuzumab duocarmazine (SYD985). In 2021, the pivotal Phase III TULIP® study of SYD985 in locally advanced or metastatic breast cancer met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement over physician's choice treatment.

The company has a dedicated team of about 400 employees. They include highly educated scientists and skilled technicians working in state-of-the-art Research and Development (R&D) laboratories and Good Manufacturing Practice (GMP) production and conjugation facilities for generating mAbs and ADCs.

Byondis collaborates with global biotechnology and pharmaceutical companies and national and international academic research institutions.

Pipeline

- Byondis has an expanding pipeline of targeted ADC and immuno-oncology (IO) therapies that are in, or approaching, the clinical study phase, including:
- Byondis' lead drug candidate [vic-]trastuzumab duocarmazine (SYD985). This ADC targets both low

- and high HER2-expressing tumors such as breast cancer, urothelial (bladder) cancer and endometrial (uterine) cancer.
- BYON3521 is an ADC that targets c-MET, the cell-surface receptor for Hepatocyte Growth Factor/ Scatter Factor (HGF/SF), which is widely overexpressed in various solid tumors.
 - BYON4413 is an ADC directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed in many hemato-oncological malignancies.
 - BYON4228 is a monoclonal antibody (mAb) from Byondis' IO program that specifically targets and blocks the CD47-SIRPα interaction, responsible for a tumor's ability to escape recognition and destruction by the immune system. CD47 is highly expressed on a wide range of tumor types.

Services and Products

- What services does your company offer?
- A focus on a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. The company produces small and large molecules and combines the two to target the disease in the right part of the body.

What products does your company make?

 - Next generation antibody-drug conjugate (ADC) technology, including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications
 - Site-Specific Antibody Conjugation
 - Monoclonal antibody (mAb) technology
 - Expertise in developing highly selective, disease-targeting small molecules

Expertise or Knowledge

In-House Capabilities

- Identifying, proposing and validating research programs for new biological and chemical entities.
- Cell line development, medium optimization, cell culture process, purification, formulations for the final product, extensive bioanalytical expertise.
- Developing linker-drug technologies for targeted conjugates and to expand our pipeline with innovative small molecules.

- Science and compliance are brought closely together in our ultramodern manufacturing facilities and quality control laboratories.
- An extensive patent portfolio that is central to the value of our business and that of our (future) licensing partners



Address

Microweg 22
6545 CM Nijmegen



Telephone

024 679 5100



E-mail

info@byondis.com



Website

www.byondis.com



Number of persons employed

± 400

Area of activity

- Product development
 - Drug development

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Biomarkers/Translation Sciences
- Pre-clinical development DMPK
- Pre-clinical development Safety and toxicology
- Clinical development phase I/II
- Clinical development phase III/Registration
- Regulatory

Area of work (indications)

Oncology and Autoimmune diseases

5.11 Check-Points

Carbapenemase producing organisms have spread globally and top the priority list of the World Health Organization as the critical AMR (antimicrobial resistance) threat. It is essential to diagnose carbapenemase resistance as fast and accurate as possible in order to control further spread.

Check-Points has developed accurate molecular assays for rapid detection of carbapenemase and ESBL resistance. These assays deliver fast results – within 2.5 hours – with very high negative predictive value and specific genotypic information on the resistance mechanism.

This saves lives, costs and protects the reputation of your hospital, so you can be confident to stay in control of AMR.

Services and Products

What services does your company offer?

- Support to our customers

What products does your company make?

- Diagnostic tests

Expertise or Knowledge

Check-Points is a pioneer in innovative DNA testing methods in the industry and health sector since its foundation in 2002. Deoxyribonucleic acid, short for DNA, is a molecule that carries the genetic instructions used in the growth, development, functioning and reproduction of all known living organisms and many viruses. Check-Points has used the specific characteristics of DNA to develop a range of rapid molecular assays which support commercial organizations and hospitals in identifying and serotyping of *Salmonella* using molecular diagnostics. Check-Points has also developed molecular assays to detect beta-lactam resistance in the form of carbapenemases, ESBLs and AmpCs within *Enterobacteriaceae*. Check-Points' innovation by DNA helps to fight serious health problems like *Salmonella* and multi-drug resistance (MDR).



Address

Binnenhaven 5
6709 PD Wageningen



Telephone

+31 (0)317 45 39 08



E-mail

info@check-points.com



Website

www.check-points.com



Number of persons employed

17

Area of activity

- Product development
 - Diagnostics
- Contract Research Organisation

Drug Discovery and Development activities pursued

- Commercial and marketing

Area of work (indications)

Hospitals

5.12 Drug Target ID (DTID)



At DTID, we have pioneered and developed a unique method to integrate ‘big’ genetic and other genome-wide data for a disease into a model that we have termed a ‘molecular landscape’.

This unbiased systems biomedicine approach offers a new platform for data integration and involves the application of not only gene enrichment and protein-protein interaction, bioinformatics-based tools, but also manual curation and iterative integration of corroborating evidence and findings from extensive literature evaluations.


To build a molecular landscape for a complex disease, we analyse the top-ranked genes that have been identified through several types of genetic, epigenetic and expression studies as well as studies on (genetic) animal models and pharmacological studies, and that have been ranked and weighted using statistical approaches.


Services and Products


The outcomes of our landscapes not only include novel and more detailed insights into the (disturbed) molecular mechanisms underlying a disease but also (novel and disease-specific) risk factors, biomarkers and drug targets that can be further developed into preventive measures, tools for more accurate and early diagnosis and disease-modifying treatments, respectively.


Expertise or Knowledge


Our concept of building a molecular landscape for a complex disease and performing preclinical studies on landscape-derived, repurposed or novel compounds specifically modulating the biological processes underlying the complex disease allows for evidence-based strategies to develop novel disease-modifying drugs, generating new therapeutic entities. Therefore, our landscapes can be exploited by pharmaceutical companies to markedly reduce their drug development costs.

**Address**
Toernooiveld 200
6525 EC Nijmegen

**Telephone**
+31 (0)6 30 34 59 56

**E-mail**
geert.poelmans@drugtargetid.com

**Website**
www.drugtargetid.com

**Number of persons employed**
6

Area of activity

- Product development
 - Drug development
 - Diagnostics

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Biomarkers / Translational Sciences
- Pre-clinical development DPMK

Area of work (indications)

In principle all complex diseases for which big (genetic) data are available (so psychiatric diseases, neurological diseases, all types of cancers etc.)



5.13 Eurofins Spinnovation Analytical

We are a provider of Analytical R&D and laboratory GMP QC testing services to the Biopharmaceutical Industry.

Eurofins Spinnovation Analytical focuses on 4 lines of businesses: 1/ NMR characterization and QC testing ; 2/ Solid-state characterization and QC testing; 3/ Root Cause Investigation (impurities, foreign matters) ; 4/ Spent Media Testing for Upstream Bioprocess Development and Troubleshooting.

We are part of the Eurofins Biopharma Product testing division (EBPT). EBPT services range from physical, chemical and microbiological quality control testing of pharmaceutical raw materials to finished dosage forms, thereby covering release, stability and validation. EBPT R&D departments can develop test methods from scratch or based on client methods. In addition to testing, EBPT has multiple aseptic manufacturing units in which small-scale compounding and fill and finish activities of clinical trial medication are performed. Labelling, packaging, storage, and distribution services are also offered. In-process and release testing as well as releasing the batch by a qualified person (QP) are included in this service.


Services


What services does your company offer?


- NMR characterization and QC testing ;
- Solid-state characterization and QC testing;
- Root Cause Investigation (impurities, foreign matters) ;
- Spent Media Testing for Upstream Bioprocess Development and Troubleshooting.


Expertise or Knowledge


- Analytical Research and Development and raw material, drug substances and drug products
- GMP QC testing
- Root Cause Investigation and Troubleshooting

**Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

**Telephone**
+31 (0)24 240 34 00

**E-mail**
Info.EBPT-NL@eurofins.com

**Website**
www.eurofins.nl

**Number of persons employed**
15

Area of activity

- Contract Research Organisation

Area of work (indications)

Anatycal R&D and GMP QC testing

5.14 European Medical Contract Manufacturing (EMCM)

European Medical Contract Manufacturing B.V. (EMCM) is a centre of excellence in developing and manufacturing (sterile) medicinal products, catering to the Biomaterials, Pharmaceuticals and Tissue Engineering markets.

Be it ampoules, vials, pre-filled syringes, pouches, bottles or blisters, from small to large scale batches, EMCM is your partner in the development and manufacturing of Pharmaceuticals and Medical Devices.

Using qualified facilities EMCM produces a broad range of medical products offering complete custom made service and product packages: from product development, through regulatory affairs, purchasing, manufacturing, final packaging, warehousing and distribution in the capacity of a contract manufacturer.

EMCM is equipped with a range of (semi-) automatic filling units for the filling of organic solvents, aqueous solutions, suspensions, gels as well as powders. All filling processes can be performed under aseptic conditions and will be validated by media simulations according GMP and ISO requirements.

Services and Products

What services does your company offer?

- Formulation of liquids, suspensions and gels
- Filling of ampoules, syringes, vials, bottles and pouches




- Powder mixing and filling
 - Tissue engineering
 - Freeze-drying
 - Sterilisation
 - Support serviced: Research & Development, Packaging, Warehousing & Logistics
- What products does your company make?
- (Sterile) Medicinal products catering to the Biomaterials, Pharmaceuticals and Tissue Engineering markets


Expertise or Knowledge

- We pair our expertise with your vision to support opportunities and bring your innovations to the market.
- EMCM is an ISO 9001:2015 and EN ISO 13485:2016 certified company and possesses a Good Manufacturing Practice Licence for the manufacturing of Pharmaceuticals.
- EMCM has the expertise to produce organic solvents, aqueous solutions and highly viscous products, like temperature dependent suspensions and gels.
- All filling processes can be performed under aseptic conditions and will be validated by media simulations according GMP and ISO requirements.




 **Address**
Middenkampweg 17
6545 CH Nijmegen

 **Telephone**
+31 (0)24 371 52 52

 **E-mail**
info@emcm.com

 **Website**
www.emcm.com

 **Number of persons employed**
50 - 99

Area of activity
• Contract Manufacturing Organisation

Area of work (indications)
Pharmaceutical and Medical Device Industry

[< Table of contents](#)

5.15 Farmaceutisch Analytisch Laboratorium Duiven

FARMACEUTISCH ANALYTISCH
LABORATORIUM DUIVEN B.V.



The principal business of FAL Duiven is the development of oral solid dosage forms for human use, registration of the various products on the Dutch market and other E.U. territories, using the most appropriate authorization route (national, MRP or DCP), followed by licensing of the dossiers to third parties for Registration in E.U. and non-E.U. territories, and subsequently the manufacture and supply of the products to its partners.

Services

What services does your company offer?


- Development, manufacturing and analysis of drug products


What products does your company make?

- Antidepressants
- Pain relief
- Sedatives
- Antivertigo

Expertise or Knowledge


- EU-GMP, GDP, GLP
- Pharmaceutical Quality System

 **Address**
Dijkgraaf 30
6921 RL Duiven

 **Telephone**
+31 (0)26 312 06 72

 **E-mail**
office@falduiven.com

 **Website**
www.falduiven.com

 **Number of persons employed**
35-45

Area of activity
• Contract Manufacturing Organisation

Area of work (indications)
Development, manufacturing and testing of generic oral solid dosage forms

[< Table of contents](#)

5.16 Future Diagnostics



Future Diagnostics is a trusted independent partner for the development of many different types of immunoassays, with different technologies, either manually or automated.



Our team of 75 highly skilled and motivated professionals is working tirelessly on product development for the detection of biomarkers. For our clients around the globe we unburden the whole process from feasibility testing to the final product. This results in a highly professional, high-quality test development in which both the demands of our clients as well as ISO 13485 and FDA regulations are considered. Our end product proves this: IVD product development by Future Diagnostics therefore means validated tests that meet the legal requirements for IVD products.

At Future Diagnostics we investigate on demand how specific markers can be measured. We determine the proper reagents to accurately measure the values with the device developed by our client. Also, we provide our

clients with the necessary protocols and process documents to ensure a well-substantiated introduction of the end product to the global market. We create the optimal starting position in order for the device and its users to do the rest. This is what makes us unique in our field.


Services and Products


What services does your company offer?

- IVD Product Development Services
- Point-of-Care Test Development
 - Multiplex Micro-Array Development
 - Colorimetric (ELISA, EIA) Assay Development
 - Fluorescent Assay Development
 - Chemiluminescent (CLIA) Assay Development
 - Turbidimetric Assay Development
 - Companion Diagnostics
 - Conjugations
 - IVDR Analytical Performance Studies
 - Verification and Validation Studies

Expertise or Knowledge


- 20+ years of expert experience on full IVD product developments
- 150+ total IVD product developments
- ISO 13485 certification and FDA registered manufacturing facility
- Highly skilled professionals guarantee a competent, efficient and optimized product development process.

 **Address**
Nieuweweg 279
6603 BN Wijchen

 **Telephone**
+31 (0)24 645 29 00

 **E-mail**
info@future-diagnostics.nl

 **Website**
www.future-diagnostics.com

 **Number of persons employed**
75+

Area of activity
Diagnostics

Area of work (indications)
Cardiovascular, infectious, autoimmune and bone metabolism diseases, oncology, endocrinology, anaemia, diabetes



5.17 GlycoMScan BV

Analytical mass spectrometry services for pharma and life sciences.

GlycoMScan offers highly sensitive and quantitative analyses in several types of biological samples like plasma, urine, cell culture media or cell extracts. We perform pharmacokinetics including pharmacokinetic modelling, and provide high level of scientific knowledge and advice. Protein glycosylation is our field of expertise. With more than 15 years of experience in science we offer high quality contract research.

Services an Products

What services does your company offer?


- Protein glycosylation analysis
- Mono- to oligosaccharide, nucleotide sugar and glycan analyses
- Pharmacokinetics
- Quantification of drugs and metabolites in plasma, cells, hair, urine etc.


What products does your company make?


- Analytical method development

Expertise or Knowledge


- Mass spectrometry
- Chromatography
- Protein glycosylation
- Omics: proteomics, metabolomics and glycomics
- Analytical chemistry
- Biochemistry
- Clinical Chemistry

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 (0)6 17 22 22 61

 **E-mail**
info@glycomscan.com

 **Website**
www.glycomscan.com

 **Number of persons employed**
1

Area of activity

- Contract Research Organisation
- Supporting pharma service

Drug Discovery and Development activities pursued

- Biomarkers / Translational Sciences
- Pre-clinical development DMPK

Area of work (indications)
Mass spectrometry analytical services in the field of biopharma, pharmacokinetics, bio-analyses, proteomics, glycomics and metabolomics analyses. Our expertise is analysis of protein glycosylation.

5.18 Glycostem Therapeutics



Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells - oNKord® - in the field of cellular immunotherapy.


Using our proprietary expansion and differentiation platform, we produce large amounts of effector cells from Umbilical Cord Blood stem cells. Products are composed of high-quality, pure and active cells.


NK cells will be the new star in the domain of cellular immunotherapy. Due to their tightly regulated “natural killing”, caused by a changed balance between activating and inhibitory cellular signals and antibody dependent cellular cytotoxicity (ADCC).


NK cells have the capability to control viral infections, target cancer and kill senescent cells. Unfortunately, our immune system can be compromised, allowing tumor cells to escape the immunological control mechanisms. Allogeneic conditions will be able to mitigate this problem. Glycostem’s concept and product pipeline is based on this principle.


A phase I/IIa trial is on-going to evaluate the safety, tolerability and efficacy of the lead product - oNKord®- patients with Acute Myeloid Leukemia (AML). During an earlier phase I trial, oNKord® showed no toxicity, expanded in vivo, migrated to the bone marrow and killed leukemic blasts.


- Services and Products**
- What services does your company offer?
- Co-development of cellular immunotherapy products including NK-cells and CAR-NK
 - Production of above
 - Regulatory and clinical support to bring products to market
- What products does your company make?
- Cellular immunotherapy product of non-manipulated or genetically modified cells
- Expertise or Knowledge**
- Research in immunotherapy arena
 - Cellular immunotherapy product development
 - Closed production system
 - Virus and vectoring technology
 - Development or co-development of cellular immunotherapy products including NK-cells and CAR-NK
 - Regulatory and clinical services

**Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

**Telephone**
+31 (0)412 21 10 01

**E-mail**
office@glycostem.com

**Website**
www.glycostem.com

**Number of persons employed**
46

Area of activity

- Product development
 - Drug development

Drug Discovery and Development activities pursued

- Target selection and validation
- Biomarkers / Translational Sciences
- Pre-clinical development Safety and toxicology
- Clinical development phase I/II
- Clinical development phase III / Registration
- Regulatory

Area of work (indications)
Blood and solid tumour cancers



5.19 HCM Medical


HCM Medical, also known as Hightech Contract Manufacturing Medical, is a Contract Manufacturing Organization specialized in the development and manufacturing of biological and biomaterial products.


Making use of different technologies, like Supercritical Fluid Extraction (SFE), Freeze-Drying, Electrospinning:


- Tissues of human and animal origin are processed into unique and high-tech medical products for various applications.
- Biomaterials are purified from tissues, like collagen and gelatin, and through Freeze Drying and Electrospinning shaped into 2- and 3-dimensional constructs for multiple applications.


For the manufacturing of medical implants, depending on the classification of the product, multiple manufacturing licensed are required and available. An extensive knowledge and experience is available for the upscaling and validation of a production process; from formulation up to packaging and sterilization.


- Services and Products**
- What services does your company offer?
- Product Development
 - Manufacturing
 - Upscaling
- What products does your company make?
- Biological Implants
 - Human Tissue constructs
 - Medical Devices
 - Collagen devices
 - Drug Release devices
- Expertise or Knowledge**
- Supercritical CO² technology (scCO²)
 - Tissue processing with scCO²
 - Freeze drying
 - Aseptic formulation & filling
 - Aseptic handling
 - Quality Management
 - Product and Process Validation
 - Registration Support

**Address**
Kerkenbos 10-113
6546 BJ Nijmegen

**Telephone**
+31 (0)24 206 29 71

**E-mail**
info@hcm-medical.com

**Website**
www.hcm-medical.com

**Number of persons employed**
1 - 10

Area of activity

- Product development
- Contract Manufacturing Organisation

Area of work (indications)
Medical Device, Tissue processing

5.20 Hycult Biotech



Hycult Biotech is a ISO-13485 certified manufacturer of research reagents in the field of innate immunity since 1994.

We have an extensive knowledge in the development and production of assays, antibodies and proteins. Our products are co-developed with leading scientists over the world. These close collaborations lead to reliable and reproducible research tools that enable better disease understanding and monitoring.

We are an experienced partner when it comes to expanding your manufacturing capabilities or out-sourcing specialized handling procedures. Our clean room facilities enable us to produce under GMP conditions and offer services such as microplate coating, lyophilization, antibody production and upscaling.

We have a scientific drive to participate in research projects and are a connection between science and industry. Hycult Biotech is a suitable SME-partner for your research project. We actively participate in international consortia and scientific grants. With our experience we can make a contribution that adds value to your project.

As manufacturer and clone license owner we can guarantee long term delivery of OEM products with firm quality and good batch-to-batch consistency. We have solid agreements on IP and cell lines and extensive knowledge, as we use these same products for our in-house development and production of assays. Our aim is to grow together, making you more successful in your business.

Services and Products

What services does your company offer?

- Antibody production, purification, custom conjugation and lyophilisation
- Reagent manufacturing, aseptic liquid filling and vial labelling
- Assay manufacturing: microplate coating, lyophilisation of standards, controls and substrates, production of buffers

What products does your company make?

- Antibodies, proteins, ELISA kits

Expertise or Knowledge

- Upscaling of antibody production
- Development of immuno assays
- GMP production of diagnostic reagents



Address
Frontstraat 2a
5405 PB Uden

Telephone
+31 (0)413 25 13 35

E-mail
info@hycultbiotech.com

Website
www.hycultbiotech.com

Number of persons employed
20-50

Area of activity

- Product development
- Diagnostics
- Contract Manufacturing Organisation

Drug Discovery and Development activities pursued

- Biomarkers / Translational Sciences
- Commercial and marketing

Area of work (indications)
Immunology; Gastrointestinal diseases; Kidney diseases; Respiratory diseases; Autoimmune diseases

5.21 ImmunoPrecise Antibodies (Europe) B.V.

ImmunoPrecise Antibodies offers a complete portfolio of antibody discovery, characterization, and production technologies.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, ImmunoPrecise offers hybridoma production, B-cell services, and a variety of phage display platforms. ImmunoPrecise also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

Services and Products

What services does your company offer?

- Stable target-expressing or antibody expressing cell line generation
- Recombinant protein or antibody productions up to 10L scale
- Immunization services (mouse, rat, rabbit, chicken, lama, transgenics)
- Hybridoma technology
- B-cell selection technology
- Phage display library generation and screening
- Antibody engineering (affinity maturation,


- humanization, bi-specifics)
- Full characterization of selected antibodies (e.g. functionality, purity, specificity, sequence liability)
- Target analysis to identify best method for above described techniques

What products does your company make?

- Antibodies
- Proteins
- Cell lines

Expertise or Knowledge

Expertise and knowledge of the full antibody discovery and development capabilities as depicted in the graphics below.



Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)412 84 60 00

E-mail
info-europe@immunoprecise.com

Website
www.immunoprecise.com

Number of persons employed
19

Area of activity

- Product development
 - Drug development
 - Diagnostics
- Contract Research Organisation
- Supporting pharma services

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding

Area of work (indications)
Biotechnology



InProcess-LSP: Innovators in Process Analytical Technology and nanoparticle sizing.

InProcess-LSP, founded in 2014, is an entrepreneurial and highly innovative organization providing advanced analytical services and solutions. InProcess-LSP will support you with addressing all of your product and process requirements. The founders have a long history working for the pharmaceutical company Organon, currently known as MSD.

With a strong background in process analytics as well as many years of academic and industrial experience we offer a highly skilled and experienced team of scientists and process specialists addressing the needs of your PAT challenges, especially in the area of nanoparticle sizing.

In 2019 a new technology was launched for nanoparticle characterization for TRUE INLINE size measurement IN FLOW: the NanoFlowSizer. As inline instrument, the NanoFlowSizer is a powerful non-invasive Process Analytical Tool allowing close monitoring of particle size characteristics in your process in either development laboratories, pilot plants or commercial operations, without the need of sampling.

- Benefits of the NanoFlowSizer:
- Average particle size and size distributions within seconds
 - Continuous size characterization of nanoparticles during processing
 - Inline (in flow) Process Analytical Tool
 - Non-invasive measurement
 - Real-time process feedback
 - Measurement of highly turbid materials
 - High speed measurement
 - Inline, online and offline operation
 - For very small (<<mL) to large sample volumes

InProcess-LSP and their laboratory, located in the Pivot Park Life Science Campus, is equipped with top-of-the-art equipment, such as low-coherence interferometry

instruments, near infrared and UV spectrometers, UV-visible spectrometers, high resolution microscopes, nano-milling equipment and more.

With a strong background in product and process development as well as in analytical sciences, InProcess-LSP offers a unique combination of tools, experience and knowledge.

Services and Products

- What services does your company offer?
- PAT Method development e.g. blend uniformity
 - assessment and content monitoring
 - Offline method development e.g. moisture content,
 - Assay/Content and residual solvents
 - Analytical Services e.g. trouble shooting and root
 - cause finding
 - Process Development & Improvement support
 - Instruments & software
 - Training on e.g. blend uniformity by NIR, PAT
 - strategies, particle sizing, DoE
- What products does your company make?
- The NanoFlowSizer, an instrument for continuous, real-time monitoring of nanoparticle size in colloidal systems, nanosuspensions, nano-emulsions and other dispersed nanoproducts directly in manufacturing processes (inline) or in a laboratory setting (offline/at line).

Expertise or Knowledge

- Process Analytical Technology (PAT)
- Instrument Development
- NanoParticle Technologies
- Pharmaceutical product and process development
- Techniques: Particle Sizing (SR-DLS) • NIR, RAMAN, NIR Imaging, Microscopy, Optical Coherence Tomography (OCT),
- Chemometrics
- Nano-milling, Homogenization

Area of activity

- Product development
 - Drug development
- Contract Research Organisation
- Supporting pharma service

Area of work (indications)

Nanoparticle Analysis in Pharma, Inks, Food, Cosmetics, Chemistry; R&D, Prod. Development, manufacturing.

Address

Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone

+31 (0)6 53 63 30 70

E-mail

sales@inprocess-lsp.com

Website

www.inprocess-lsp.com

Number of persons employed

10

5.23 Khondrion



Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.



The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases. To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally. Khondrion is headquartered in Nijmegen, The Netherlands.

Products

What products does your company make?
Khondrion’s lead asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical develop-

ment to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. The phase 2A KHENERGY study, published in September 2018, showed consistent pharmacokinetic, safety and tolerability data for KH176, and significant improvement in a number of clinical endpoints which supported further development of the potential medicine. Planning for KHENERGYZE, a dose-exploration phase IIb study, is now underway with the first patient in that study expected to be dosed in Q2-3 2019. KH176 has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. Preclinical research is underway exploring the potential of Khondrion’s pipeline to target diseases resulting from a cellular reduction–oxidation (redox) imbalance. Redox imbalance occurs when the redox signaling processes in cells – the fundamental processes by which cells detect damage and then start their repair mechanisms – are not controlled. Diseases currently under investigation include genetic forms of Parkinson’s disease, congenital muscular dystrophy and inborn errors of metabolism.

Expertise or Knowledge

- Mitochondrial medicine
- Drug development

Address
Philips van Leydenlaan 15
6525 EX Nijmegen

Telephone
+31 (0)24 361 75 05

E-mail
info@khondrion.com

Website
www.khondrion.com

Number of persons employed
7

Area of activity

- Drug development

Drug Discovery and Development activities pursued

- Clinical development phase I/II
- Clinical development phase III/ Registration
- Regulatory

Area of work (indications)
Diseases and conditions with disturbed redox-metabolism. Focus on mitochondrial diseases



5.24 LiteVax

LiteVax BV is a biopharmaceutical company focusing on the development and exploitation of novel adjuvant concepts

Our mission is to contribute to global health by delivering improved adjuvants for vaccines against infectious and noninfectious diseases. People in developed and developing countries will benefit from better vaccines at lower costs.

Services and Products

What products does your company make?

- Vaccine adjuvants

Expertise or Knowledge

- Organic chemistry
- Pharmaceutical formulation technology
- Vaccine development

Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)6 23 36 78 12

E-mail
info@litevax.com

Website
www.litevax.com

Number of persons employed
1-5

Area of activity

- Product development
 - Drug development

Drug Discovery and Development activities pursued

- Pre-clinical development Safety and toxicology

Area of work (indications)
Organic chemistry, vaccine formulation technology

5.25 Lead Pharma



Lead Pharma is a small pharmaceutical company that discovers, develops and commercialises innovative therapeutics against cancer and autoimmune diseases.

Lead Pharma has an attractive pipeline of first-in-class and best-in-class projects in various stages of research and development varying from target selection through pre-clinical development. Lead Pharma has the ambition to expand its capabilities to cover all the R&D stages up to and including early clinical development to Proof of Concept.

Expertise or Knowledge

- Cellular Pharmacology
- Molecular Pharmacology
- Computational Chemistry
- Medicinal Chemistry
- Pre-clinical development, cmc, toxicology, early clinical development

Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)412 78 29 99

E-mail
info@leadpharma.com

Website
www.leadpharma.com

Number of persons employed
30

Area of activity

- Product development
 - Drug development

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Biomarkers / Translational Sciences
- Pre-clinical development DMPK
- Pre-clinical development Safety and toxicology
- Clinical development phase I/II



5.26 Luminex

At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.

We serve the needs of our customers in diverse markets including clinical diagnostics, pharmaceutical drug discovery, life science research, immunology, and personalized medicine. Our goal is to transform global healthcare with innovative instruments and assays that deliver cost-effective, rapid results to clinicians and researchers. For further information, please visit www.luminexcorp.com.



Services and Products

What services does your company offer?

- Multiplexing technology (xMAP®)
- (Imaging) Flow Cytometry
- Molecular Diagnostics Solutions
- Service & Support
- Trainings

What products does your company make?

- Magpix®
- Luminex®200™
- FLEXMAP 3D®
- Microspheres
- AMNIS® ImageStream
- AMNIS® Flowsight
- AMNIS® CellStream
- Guava® EasyCyte
- MUSE® Cell Analyzer
- ARIES®
- VERIGENE®

Expertise or Knowledge

- Multiplexing technology
- Instruments
- (Imaging) Flow Cytometry
- Molecular Diagnostics

Address
Het Zuiderkruis 1
5215 MV 's-Hertogenbosch

Telephone
+31 (0)73 800 19 00

E-mail
europe@luminexcorp.com

Website
www.luminexcorp.com

Number of persons employed
50-100

Area of activity

- Product development
 - Diagnostics

Drug Discovery and Development activities pursued

- Target selection and validation
- Biomarkers / Translational Sciences

Area of work (indications)

Instrument manufacturer, our technology is suitable for Drug Discovery.


5.27 MDxHealth





MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.


The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.


- Services and Products**
- What services does your company offer?
- Service testing Select MDx
- What products does your company make?
- Confirm MDx Selection Kit
 - Select MDx Amplification Kit & reporter Application

**Address**
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

**Telephone**
+31 (0)88 327 27 27

**E-mail**
info@mdxhealth.com

**Website**
www.mdxhealth.com

**Number of persons employed**
51 - 200

Area of work (indications)
Molecular Diagnostic company

5.28 Medimmune Pharma (Astra Zeneca)



MedImmune Pharma is the worldwide biologics business for the AstraZeneca Group.



The company has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands.


With two marketed products and an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health.


MedImmune is located since 1993 at Lagelandseweg 78 in Nijmegen. At our Nijmegen manufacturing facility, we produce vials of drugs for research and commercial purposes, meeting a range of needs from potential cancer cures to vaccinations for premature babies.


The facility consists of production, labelling and packaging, quality control, quality assurance, materials management, facilities and a host of other areas. MedImmune is a part of AstraZeneca since June 2007.


We are located in Nijmegen and the majority of our employees come from Brabant, Gelderland and Limburg. Our products find their use all over the world. On February 14, 2019, it was announced that the MedImmune name and branding would be discontinued in favour of AstraZeneca.


- Services and Products**
- Fill/finish of liquid and lyophilized parenteral product

**Address**
Lagelandseweg 78
6545CG Nijmegen

**Telephone**
+31 (0)24 371 73 10

**E-mail**
info_nl@medimmune.com

**Website**
www.astrazeneca.com

**Number of persons employed**
51 - 200

5.29 Memidis Pharma



Memidis Pharma is a gynaecology and urology dedicated pharmaceutical company.

We understand that success lays with strong and durable partnerships where complementing our know-how with the expertise of excellent partners is the key to success.


Within the field of Urological and Gynaecologic diseases there are still patients with highly unmet needs. To meet these needs we need to market or develop innovative products that have substantial clinical added value for doctors and patients.


We are open for in-licensing or acquisition opportunities.


Memidis Pharma has become a reliable partner in uro-gynecology by marketing a broad range of innovative products for Women's & Men's Health.


We are constantly searching for new treatment options in this field. With our expertise in the uro-gynecology market in the BENELUX we are a well-positioned partner and are able to bring products successfully to the market.

- Services and Products**
What services does your company offer?
- Develop innovative products
 - Market innovative products
- Expertise or Knowledge**
We are constantly searching for new treatment options in this field. With our expertise in the uro-gynecology market in the BENELUX we are a well-positioned partner and are able to bring products successfully to the market.

**Address**
Kerkenbos 1077-R
6546 BB Nijmegen

**Telephone**
+31 (0)24 645 54 11

**E-mail**
info@memidis.nl

**Website**
www.memidis.nl

- Area of activity**
- Product development
 - Drug development
 - Medical technology
- Drug Discovery and Development activities pursued**
- Commercial and marketing
- Area of work (indications)**
Gynaecology Urology Generics

5.30 Mercurna




Mercurna is developing a platform for the delivery of messenger RNA (mRNA) to a variety of tissues.


Using lipid, polymers and/or peptides, we are generating nano-particles capable of delivering mRNA with high efficiency to a variety of tissues in a targeted manner. Currently, our main focus is to bring a first drug into the clinic. This drug will serve as a proof-of-principle of the platform as a whole and will provide a valuable treatment for patients with Chronic Kidney Disease.


Chronic kidney disease (CKD) is a great unmet clinical need, covering a wide-spectrum of diseases, commonly denominated by progressive damage and inflammation of the glomerulus (the filter of the kidney). More than 850 million people are affected worldwide and yet no medication exists that is able to fully stop or even reverse the course of the disease.


Mercurna's mRNA-based drug for CKD would target a unique combination of pathogenic pathways and we aim thereby to provide an unprecedented high efficacy and minimal side effects.

- Services and Products**
What services does your company offer?
- Custom mRNA synthesis and purification
- What products does your company make?
- Novel drugs against various indications
- Expertise or Knowledge**
- Nano-particles / delivery systems
 - Messenger RNA
 - Targeted delivery
 - Nano-particle drug discovery

**Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

**E-mail**
info@mercurna.com

**Website**
www.mercurna.com

**Number of persons employed**
3

- Area of activity**
- Product development
 - Drug development
- Drug Discovery and Development activities pursued**
- Target selection and validation
 - Hit identification
 - Lead finding
 - Pre-clinical development DMPK
 - Pre-clinical development Safety and toxicology
 - Clinical development phase I/II
- Area of work (indications)**
- Chronic Kidney Disease
 - Various undisclosed indications

5.31 MSD Animal Health



MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of companion animals (such as dogs, cats, and horses) and livestock (ruminants, pigs, poultry, and farmed fish). The company offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary medicines, vaccines and veterinary services.

MSD Animal Health in the Netherlands has locations in Boxmeer and De Bilt. The campus in Boxmeer is the world's largest center for the development and production of veterinary vaccines. About 1400 people work at MSD Animal Health in the Netherlands. One in eight people works in research and development, while around half of the total staff works in manufacturing and quality control. The remaining employees work in support departments and services. The sales organization for the Netherlands is also based in Boxmeer. This one location houses many important functions for vaccine development (research, development, production, quality control, logistics, marketing and sales). Thanks to the incredible amount of knowledge, expertise and experience possessed by its employees, MSD Animal Health in Boxmeer is a Center of Excellence.


Services and Products


What products does your company make?


- Vaccine for animal health
- Pharmaceuticals for animal health
- Biologics for animal health
- Health support/platform for farmers and food producing industries

Expertise or Knowledge


- Bacteriology, virology and parasitology
- Host-pathogen interactions
- Vaccine technology
- Process development/fermentation/cell culture
- Immunology/assay development/Immune stimulation/Adjuvants
- Disease models
- Animal Health

 **Address**
Wim de Körverstraat 35
5831 AN Boxmeer

 **Telephone**
+31 (0)485 58 76 00

 **E-mail**
Info.ah.nl@merck.com

 **Website**
www.msd-animal-health.nl

 **Number of persons employed**
1500

Area of activity

- Product development
 - Drug development
 - Medical technology
 - Diagnostics

Drug Discovery and Development activities pursued

- Target selection and validation
- Biomarkers / Translational Sciences
- Clinical development phase III / Registration
- Regulatory
- Commercial and marketing

5.32 NanoServe BV



NanoServe BV develop and designs customized nanoparticle structures and compositions fitting the property requirements of our clients.

NanoServe's technology enables to modulate the physicochemical properties of the nanoparticles according to specific applications, as to take benefit from their advantages while minimizing their risks on human health. Our technique allows non-toxic and safe encapsulation of active ingredients, design of resorbable biomaterials, creation of diagnostic products, and the creation of active particles by themselves. The biosolubility character confers to the new nanoparticles a great promise in a range of applications, which makes them powerful candidates with respect to conventional insoluble nanoparticles.


Services and Products


What services does your company offer?


- Nanotechnological design, analytics and consultancy
- What products does your company make?
- Safe and sustainable biomaterials

Expertise or Knowledge


- Nanotechnology
- Nanoparticles, Microparticles, Nano-encapsulation
- Biosolubility
- Nano analytics
- Nano safety

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 (0)6 41 47 17 84

 **E-mail**
atijani@nanoserve-international.com

 **Website**
www.nanoserveinternational.com

 **Number of persons employed**
3

Area of activity

- Product development
 - Drug development
 - Medical technology
 - Diagnostics
- Contract Research Organisation
- Supporting pharma service

Area of work (indications)

Nanotechnology within pharmaceutical applications, life sciences and other disciplines.

5.33 NeuroDrug Research (NDR)



NeuroDrug Research tests pharmacological compounds in human brain organoids to discover new treatments for Multiple Sclerosis (MS).

We integrate big genetic and other genome-wide data into a so-called molecular landscape of MS to gain insight into the core molecular pathways underlying MS, and to identify risk factors, biomarkers and key targets.

Functional studies on key targets from the molecular landscape of MS in 3-D mini-brains (cultured human stem cells developed into oligocortical spheroids) include examining the effects of genetic modification and pharmacological manipulation of the MS-associated key target proteins. Furthermore, we use CRISPR-cas to generate mini-brains defective in MS-associated key targets and test pharmacological compounds to restore the functioning of the MS mini-brains.

Address
Mercator III
Toernooiveld 1
6525ED Nijmegen

Telephone
+31 (0)6 33 71 00 09

E-mail
g.martens@ncmls.ru.nl

Website
N/A

Number of persons employed
4-7

- Services and Products**
What products does your company make?
 - Drug testing in (MS) human brain organoids
 - Big data curation to gain insight into molecular mechanisms underlying MSWhat products does your company make?
 - (MS) Human brain organoids
 - New leads for the treatment of MS
- Expertise or Knowledge**
 - Big data curation
 - Insights into molecular mechanisms relating to MS
 - (MS) Human brain organoids
 - Genetic and pharmacological testing

- Area of activity**
 - Product development
 - Drug development
 - Diagnostics
 - Contract Research Organisation
- Drug Discovery and Development activities pursued**
 - Target selection and validation
 - Hit identification
 - Lead finding
 - Biomarkers / Translational Sciences
- Area of work (indications)**
Molecular and cellular neurobiology; big data analysis; functional studies and drug testing using human brain organoids

5.34 Noviocell



Noviocell BV is a highly innovative biotech company. It focuses on the development of the first ever synthetic solution for 3D cell culturing, ranging from organoid growth to personalized medicine.

Noviocell will build upon its two proprietary hydrogel technologies; the soft thermo-responsive helical oligo(ethylene)glycol polyisocyanopeptides (PICs) hydrogel and the programmed self-assembly of peptide-modified cyclohexane triacid derivatives into self-assembled nanofibers and develop them into easy-to-use solutions for biomedical researchers, biotech and pharma industry and clinicians.

The potential of 3D cell culturing is evident: never before have we been able to assess the complexity of (human) biology in such a detailed manner. Recent highlights include brain, liver and disease-specific organoids (which especially have shown tremendous value in combination with gene editing technology such as CRISPR/CAS). These will contribute to our understanding of health and disease as well as identification of new therapeutic targets and biomarkers. But to fully leverage the potential of 3D cell culturing it is necessary to address three key bottlenecks: robustness, scalability and clinical use.

The most commonly used matrices are from animal origin. This leads to batch-to-batch variability resulting in inconsistencies in results. Noviocell will build upon its synthetic hydrogels and develop them into easy-to-use solutions. The unique combination of tunable biofunctionality and biomechanics of the hydrogels make them excellent matrices for 3D cell culture or regenerative medicine.

- Services and Products**
What products does your company make?
 - Synthetic hydrogels for 3D cell culture
- Expertise or Knowledge**
 - Polymer chemistry
 - Cell biology: stem cells, organoids and spheroids



Address
Pivot Park
Kloosterstraat 9
5349 AB Oss

Telephone
+31 (0)6 22 30 32 19

E-mail
info@noviocell.com

Website
www.noviocell.com

Number of persons employed
5

Area of activity

- Product development
 - Medical technology
 - Diagnostics

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Pre-clinical development Safety and toxicology

Area of work (indications)
Life Science Research market

5.35 NYtor



NYtor was founded in 2007 by Jacqueline Vet (co-inventor of the molecular beacon probe technology). NYtor employs an enthusiastic and motivated team of PhDs and research technicians with ample experience and state-of-the-art knowledge of molecular diagnostic assay development. Initially, the Nijmegen-based company was located at the University campus. However, to enable further growth, NYtor moved in January 2014 to its current location, a prominent place directly behind the historic St. Stephanus church.

What we do

NYtor designs and develops molecular detection assays in the field of human and veterinary diagnostics. Our main focus is the development of smart molecular assays for the detection of antibiotic resistance. In close harmony with our customer, NYtor develops prototype assays and works together with a broad network of carefully selected suppliers and partners. Based on your demand NYtor can support design, development and prototype kit production. Currently NYtor is in the transition towards ISO 13485 certification.

Examples of commercial assays of which the prototype assays are developed by NYtor are:

- ESBL and CPE qPCR assays (Check-Points, Wageningen, NL)
- TVMGRES qPCR (PathoFinder, Maastricht, NL)
- Poultry/Swine pathogen detection qPCR assays (BioChek, Reeuwijk, NL)

Innovation

Ultra-sensitive detection and quantitation of mutations.
To detect rare tumor cells in the presence of abundant normal cells, SuperSelective primers are used to develop low-cost, sensitive (~0,01%), specific, and highly multiplexed (up to 20) qPCR assays. NYtor works in close collaboration with the inventors of the SuperSelective primer technology (Department of Molecular Genetics,

PHRI, Rutgers University, Newark) enabling efficient development of these innovative assays.

Point of Care (PoC) applications using molecular beacons.
In addition to their use in PCR, molecular beacons can be applied in isothermal amplification assays or as detector probes on biosensors and are therefore a perfect tool for PoC applications. Due to their hairpin structure molecular beacons are extremely specific and can easily discriminate single-nucleotide

Services and Products

What services does your company offer?

- Development of prototype smart molecular diagnostic kits

What products does your company make?

- NYtor develops prototype molecular diagnostic kits and works together with other companies that perform final validation, production and sales. The kits are mainly used in diagnosis of infectious diseases/antibiotic resistance and early screening of cancer.

Expertise or Knowledge

- Real-time PCR
- Isothermal amplification
- Primer - Probe technologies
- Assay development


Area of activity


- Product development
 - Diagnostics
- Contract Research Organisation

Drug Discovery and Development activities pursued


- Target selection and validation

 **Address**
Berg en Dalseweg 199
6522 BJ Nijmegen

 **Telephone**
+31 (0)24 711 03 53

 **E-mail**
info@nytor.nl

 **Website**
www.nytor.nl

 **Number of persons employed**
5 - 9



5.36 Osteo-Pharma

Osteo-Pharma BV develops novel medication and medical devices for orthopedic and dental applications for the local treatment of bone fractures and bone defects.

Osteo-Pharma's technology platform is based on applying local sustained delivery of low molecular weight compounds that enhance bone formation while simultaneously inhibiting bone resorption. Osteo-Pharma was founded in Januari 2014 and applies novel technology to deliver pharmaceuticals locally near to a bone fracture or bone defect. By encapsulating pharmaceuticals in a biodegradable carrier sustained release of pharmaceuticals over a 6-8 week period is achieved. During this period bone growth is enhanced and bone resorption is inhibited resulting in a net effect of bone growth. This technology is now in development to improve the healing of bone fractures, bone defects and for the treatment of osteoarthritis. In addition, Osteo-Pharma is developing a novel coating for dental and orthopedic implants to improve osseo-integration and to prevent implant loosening.


Services and Products


What products does your company make?


- Medical Devices (Class 3)
- Pharmaceuticals

Expertise or Knowledge


- Bone biology
- Bone fracture healing
- Controlled and sustained drug release technology

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 (0)85 025 00 21

 **E-mail**
info@osteo-pharma.com

 **Website**
www.osteo-pharma.com

 **Number of persons employed**
3

Area of activity

- Product development
 - Drug development
 - Medical technology

Drug Discovery and Development activities pursued

- Pre-clinical development DMPK
- Pre-clinical development Safety and toxicology
- Clinical development phase I/II
- Clinical development phase III / Registration

Area of work (indications)

Regenerative medicine, Drug development, Controlled release systems, Orthopedics, Dental

5.37 PharmaCytics



PharmaCytics is a pharmaceutical Research company, specialized in synthetic chemistry, and produces bioactive molecules to study and manipulate biological systems.

The company has extensive expertise on medicinal chemistry, prodrugs, linkers, and drug delivery, with special emphasis on nutrient-drug conjugates.

We are a team of scientists and business experts, highly motivated to develop new and value-added therapies to relieve medical issues of patients. Our focus is to provide innovative solutions to improve suboptimal properties of small-molecule drugs and therapeutic peptides. One of our main drug delivery projects is to facilitate transport of biomolecules through cellular membranes. By combining knowledge of cellular processes with medicinal chemistry expertise, we have developed proprietary technology to solve bioavailability issues of (oral) medication by exploiting the transport capacity of specific carrier proteins. Our technology also holds promise to facilitate uptake of anticancer drugs into tumor cells and to enable passage of CNS active compounds through the blood-brain barrier.

**Address**
Novio Tech Campus
Transistorweg 5v
6534 AT Nijmegen

**Telephone**
+31 (0)85 044 03 10

**E-mail**
info@pharmacytics.com

**Website**
www.pharmacytics.com

**Number of persons employed**
10 - 15

Services and Products
What services does your company offer?

- Drug delivery: improving oral bioavailability of small molecule drugs and therapeutic peptides by applying advanced prodrug technologies
- Application of linker technologies to prepare nutrient-drug conjugates, drug-drug conjugates and drug-protein conjugates

What products does your company make?

- Improved versions of small molecule drugs and therapeutic peptides

Expertise or Knowledge

- Prodrug technologies
- Linker technologies
- Drug delivery
- Lead optimization

Area of activity

- Product development
 - Drug development

Drug Discovery and Development activities pursued

- Lead finding

Area of work (indications)
Oncology, immunology, cardiovascular, CNS

5.38 PharmSupport



PharmSupport provides staffing and expertise in the field of quality and compliance to the pharmaceutical industry, food industry, hospital world and other organizations to which comparable quality requirements apply.


Our vision is that quality improvement and increasing efficiency & effectiveness can go hand in hand. “First Time Right” and “Lean Six Sigma” are therefore key cornerstones of our services. Our mission is to provide expertise and support that perfectly matches the needs of our customers. We focus on the Right First Time improvement of the general quality, GMP and regulatory compliance level of our clients, so that the requirements of the national and international supervisory authorities are met.


Services and Products
What services does your company offer?


- Consultancy & audits
- Quality as a Service
- Training & education
- Staffing (through PharmSupport-Flexwerk N.V.)


Expertise or Knowledge


- Development, implementation, assessment, monitoring and coordination of GMP, GDP, GAMP, GDS, ISO 9001, ISO 13485 quality management systems
- Audits, preparation & follow-up of inspections
- Screening of - and support with application for - required pharmaceutical licenses
- Pharmaceutical risk assessments, including GDS, warehousing and distribution
- Establishment and implementation of (risk based) CAPA plans
- Qualification and validation of pharmaceutical equipment, utilities, facilities, systems and processes, including automation
- Development, implementation, assessment, monitoring and coordination of serialisation requirements according FMD.

**Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

**Telephone**
+31 (0)412 71 20 92

**E-mail**
info@pharmsupport.nl

**Website**
www.pharmsupport.nl

**Number of persons employed**
7

Area of activity

- Supporting pharma service

Drug Discovery and Development activities pursued

- Regulatory
- Commercial and marketing

Area of work
GMP, GDP, GxP, auditing, training, deviation management, risk management, change control, validation, qualification, medical devices, CFR 820, ISO 13485

5.39 Pivot Park Screening Centre



Pivot Park Screening Centre (PPSC) provides drug discovery services in the field of assay development, lab automation, (ultra) High Throughput Screening ((u)HTS)) and hit-2-lead testing to find novel leads for drug development.

The screening facility includes state-of-the-art robotic systems, instrumentation for biological profiling and a collection of 300,000 high quality drug-like compounds. Established in 2012 as a spin-off from Organon / MSD, PPSC uses a new, open innovation approach to build on the long-established history of screening in Oss, the Netherlands. PPSC is located on Pivot Park, an inspiring life sciences campus for open innovation in the life sciences with focus on pharmaceutical R&D.

Services and Products

What services does your company offer?


- ultra High Throughput Screening - We offer state-of-the-art automation for low to ultra-High Throughput Screening to find and optimize novel leads for drug development. We can help you miniaturize your assays to 96-, 384- or 1536-well formats for Low, Medium or High Throughput Screening including hit validation, hit-to-lead and lead optimization.
- Assay Development - Our experienced team provides you with tailored biochemical and cellular assay solutions to find leads for your target class. We facilitate every unique drug discovery project with a wide range of measurement technologies. Currently we also perform assay development from scratch for a few big pharma companies.
- Compound Library – We have a high quality compound library available for your drug discovery screens performed at PPSC. For screening projects we offer a compound library of 300,000 high quality drug-like


compounds. It is a diverse set of compounds that can be applied to a wide range of targets. It includes subsets of known drugs (~1200) and reference compounds (~400) that can be used for assay validation and drug-repurposing studies. In addition we can also screen on the compound set of our customers.


- Hit triaging - Our expertise ranging from assay development and in-vitro pharmacology to medicinal chemistry (at partners) and high-content screening helps you navigate your hit list and triangulate the most promising leads in different therapeutic areas.
- Open Access Lab - Our open access laboratory is designed to provide you with the experienced technical staff and easy-to-use automation infrastructure for assay development, screening, hit-to-lead, high content analysis and technology development. The open access lab at PPSC gives you a fast and direct access to laboratory space, a broad selection of instruments and specialised supporting staff without large investments. You can flexibly scale up your experiments and efficiently run your own biology using our automation and expertise.


Expertise or Knowledge


- Pivot Park Screening Centre's expertise lies in providing drug discovery services in the field of assay development, lab automation, (ultra) High Throughput Screening ((u)HTS)) and hit-2-lead testing to find novel leads for drug development.

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 (0)412 84 60 50

 **E-mail**
screeningsecretariaat@ppscreeningcentre.com

 **Website**
www.ppscreeningcentre.com

 **Number of persons employed**
30

Area of activity

- Contract Research Organisation

Drug Discovery and Development activities pursued

- Target selection
- Hit identification
- Lead finding

Area of work (indications)
Thanks to our extensive experience we're able to provide Assay Development and Compound Screening (biochemical and cellular, mostly in 1536-well format) and Hit2Lead support for a wide variety of indications.



5.40 Pleco Therapeutics

Developing new products in the field of cancer medicine.

Pleco develops fixed-dose combinations (FDCs) for the treatment of cancer. These FDCs modify the cancer-generating environment by reducing the high load of known carcinogenic compounds that have accumulated in the body over many years. At MD Anderson Cancer Center in Houston, Texas, investigators have established that these carcinogenic compounds contribute to relapses in leukaemia patients.

All components in our FDCs are known active pharmaceutical ingredients (APIs) with established safety and efficacy profiles. Repurposing of existing therapies for alternate diseases is an attractive approach that saves significant investments of time and money during development.


Products


What products does your company make?

- Combination therapy in the field of cancer

Expertise or Knowledge


- Pharmaceutical business and drug development

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Telephone**
+31 (0)6 11 32 55 10

 **E-mail**
info@plecotherapeutics.com

 **Website**
www.plecotherapeutics.com

 **Number of persons employed**
4

Area of activity

- Product development
 - Drug development

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- lead finding
- Biomarkers / Translational Sciences
- Pre-clinical development DMPK
- Pre-clinical development Safety and toxicology
- Regulatory

Area of work
Development of treatment in cancer

5.41 ProtActivity



ProtActivity focusses on the development of vaccines against protozoal diseases.



The aim is to bring effective vaccines and diagnostics to the market in order to improve animal health, and sustain food production. We have broad experience in antigen discovery, vaccine formulation, production, quality control and registration worldwide. We collaborate with partners in research projects on contract basis, and give advice and support to our customers on specific topics on a consultancy basis. Partners profit from our broad network with universities, industry, governmental and non-governmental organizations.

- Services and Products**
What services does your company offer?
 - Advice and support to partners to the development of vaccinesWhat products does your company make?
 - Vaccines against protozoa
 - Vaccines against haemoparasites (ticks)
- Expertise or Knowledge**
 - Commercial vaccine development
 - Ticks and tick borne diseases
 - Infectious diseases (pathogenesis and immunology)
 - Tropical animal health

- Address**
Sering 36
5432 DD Cuijk
- Telephone**
+31 (0)6 15 00 68 39
- E-mail**
th.schettters@protactivity.com
- Website**
www.protactivity.com
- Number of persons employed**
1

- Area of activity**
 - Product development
 - Drug development
 - Contract Research Organisation
- Drug Discovery and Development activities pursued**
 - Target selection and validation
 - Hit identification
 - Biomarkers / Translational Sciences
 - Pre-clinical development Safety and toxicology
 - Clinical development phase I/II
 - Clinical development phase III / Registration
 - Regulatory
- Area of work (indications)**
Vaccines against ticks and tick borne diseases

5.42 Protinhi Therapeutics



Protinhi Therapeutics is an early stage biotech company, developing novel drugs against diseases with a high unmet medical need using proprietary technology and compounds that target diseases via Protease Inhibition. The focus of Protinhi is on upcoming viral threats and particularly on Dengue and Zika.

- Services and Products**
What products does your company make?
 - Lead compounds for outlicensing
- Expertise or Knowledge**
 - Drug development
 - Medicinal chemistry
 - Assay development
 - Bioinformatics
 - Molecular modelling
- Address**
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen
- E-mail**
info@protinhi.com
- Website**
www.protinhi.com
- Number of persons employed**
3
- Area of activity**
 - Product development
 - Drug development
- Drug Discovery and Development activities pursued**
 - Target selection and validation
 - Hit identification
 - Lead finding
 - Pre-clinical development DMPK
 - Pre-clinical development Safety and toxicology
 - Clinical development phase I/II
 - Regulatory
 - Commercial and marketing
- Area of work (indications)**
Virology





QM Diagnostics is an internationally operating, independent and innovative diagnostic microbiological laboratory.


We are specialized in health monitoring of small laboratory animals used for biomedical research. To help our clients getting the most out of our services, we provide a wide range of complementary consultancy services as well.


We believe that sharing our vast experience and our innovative spirit, with our clients and with our scientific partners, leads to better diagnostics and increased certainty. Something we all, including the laboratory animals, benefit from. Sharing knowledge has become part of our DNA, and it guides everything we do today – it is contagious.

- Services and Products**
What services does your company offer?
- Diagnostic services for microbiology, serology, parasitology and molecular diagnostics
 - Consultancy in Laboratory animal science
 - Test development related to pathogen detection
- Expertise or Knowledge**
- Test development (serological assays, molecular assays, microbiological techniques)
 - Rodent, rabbit and Zebrafish health monitoring
 - Pathogens relates to Laboratory animals
 - Assessing health risk in animals facility

**Address**
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

**Telephone**
+31 (0)24 361 54 33

**E-mail**
qmdiagnosics@qmdiagnosics.org

**Website**
www.qmdiagnosics.org


- Area of activity**
- Product development
 - Diagnostics
- Area of work (indications)**
Diagnostics


QPharmetra helps drug development companies bring new medicines to market more efficiently by using clinical pharmacology and pharmacometric analysis to help choose the dose, identify the best patient population, design trials, position drugs in the competitive landscape and effectively support these decisions to regulators.


Using a variety of the latest pharmacometric tools and techniques we work to integrate all available data, creating sophisticated mathematical models to make rational development decisions and provide clear and robust reports to support the decisions.


- Expertise or Knowledge**
- Modeling & simulation
 - Pharmacokinetics
 - Statistics
 - Clinical Drug Development
 - Software

- Services**
What services does your company offer?
- Pharmacometric Consulting
 - Clinical Pharmacology Consulting
- What products does your company make?
- Customized Software Solutions supporting Pharmacometrics

**Address**
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

**Telephone**
+31 (0)6 18 80 22 92

**E-mail**
klaas.prins@qpharmetra.com

**Website**
www.qpharmetra.com

- Area of activity**
- Contract Research Organisation
 - Supporting pharma service
- Drug Discovery and Development activities pursued**
- Biomarkers / Translational Sciences
 - Pre-clinical development DMPK
 - Clinical development phase I/II
 - Clinical development phase III/Registration
- Area of work (indications)**
Pharmacometrics & Clinical Pharmacology

5.45 Smivet



Smivet BV was founded in 2013 in the Netherlands. The mission of this start-up company is to bring new innovative veterinary medicinal products to the market and by doing so contribute to Animal Health.


The company focuses for its internal research pipeline on projects that deliver products for niche markets. The laboratory was established in Nijmegen in 2017.

Smivet can also be your partner in the research, development and licensing of veterinary medicinal products and diagnostics.

We can support you with Regulatory Affairs activities, Due Diligence activities and R&D activities.

Services and Products

- What services does your company offer?
- Single domain antibody platform(s) for animals
 - Single domain antibody product development
 - Consultancy on R&D of VMP, regulatory affairs for VMPs, and interim management in these areas.



Copyright Smivet BV

What products does your company make?

- VMPs based on single domain antibodies.
- Scientific reports on requested research topics.

Expertise or Knowledge

- Veterinary science (Virology, Bacteriology, Immunology)
- Veterinary preclinical VMP research
- Veterinary clinical development
- Veterinary Regulatory affairs
- Therapeutic single domain antibody development
- Management experience with research teams
- Broad experience in the veterinary pharma industry



Address
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

Telephone
+31 (0)6 51 29 36 52
+31 (0)24 200 12 60

E-mail
info@smivet.com

Website
www.smivet.com

Number of persons employed
2

Area of activity

- Product development
 - Drug development
 - Diagnostics
- Contract Research Organisation

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Pre-clinical development Safety and toxicology
- Clinical development phase III / Registration
- Regulatory

Area of work (indications)

Veterinary medicine (incl one health targets), research and development of veterinary medicinal products (VMP)

[< Table of contents](#)



5.46 SPL Medical

The purpose of SPL Medical is to save the lives of cancer patients with novel diagnostic imaging solutions that allow a more effective and safe therapy. SPL does that by enabling radiologists and medical professionals to make an effective and specific detection of lymph node metastasis.

The Radboud University Medical Center (Radboudumc) has its sights set on being a leader in the development of sustainable, innovative, and affordable healthcare. Professor Dr. Jelle Barentsz, radiologist at the Radboudumc, received in 2007 the Queen Wilhelmina Research Prize from KWF Kankerbestrijding for the application of new MRI techniques to better map prostate cancer and possible metastases. This Dutch foundation 'Fight against cancer' is a close partner of Raboudumc. Their subsidy has made possible the start-up of the development of Ferrotran.

The contrast agent Ferrotran has been used succesfully at Radboudumc in hundreds of cancer patients. Through new investments by the German pharmaceutical company b.e. imaging GmbH and Dutch development company PPM Oost, SPL Medical wants to finance European registration of Ferrotran to enable the diagnosis of prostate cancer metastases in the lymph nodes. Later additional indications will follow.

Services and Products

What products does your company make?

- Contrast agent for (early) detection of lymph node metastases in prostate cancer in MRI

Expertise or Knowledge

- Contrast agents market
- Clinical research
- IP
- Certain pharmaceutical manufacturing steps
- Regulatory

Address
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

Telephone
+31 (0)24 303 10 90

E-mail
info@splmed.com

Website
www.ferrotran.com

Area of activity

- Product development
 - Drug development
 - Diagnostics

Drug Discovery and Development activities pursued

- Clinical development phase III / Registration
- Commercial and marketing

Area of work (indications)

(Early) Detection of lymph node metastases in prostate cancer in MRI

[< Table of contents](#)

5.47 Symeres



Symeres is the leading mid-sized European drug-discovery contract research organization for solving your chemistry challenges. From the design and synthesis of small to medium-sized molecule hits, to the delivery of first GMP batches of identified clinical candidates.

For over 25 years we blend vast scientific knowledge and inventiveness to make great leaps on your behalf. We go further to unlock new potential.

As your preferred chemistry partner, we aim to create your value by combining our synthetic power, collective intelligence, medchem insights and CMC know-how.

Expertise or Knowledge

Providing Chemistry solutions in the following areas:

- Discovery Chemistry
- Medicinal Chemistry
- Parallel Chemistry
- Process Research Chemistry
- Scale-up synthesis
- GMP Synthesis



Address

Kerkenbos 1013
6546 BB Nijmegen



Telephone

+31 (0)24 372 33 00



E-mail

info@symeres.com



Website

www.symeres.com



Number of persons employed

300

Area of activity

- Contract Research Organisation
- Contract Manufacturing Organisation
- Supporting pharma service

Drug Discovery and Development activities pursued

- Hit identification
- Lead finding

Area of work (indications)

Mainly (Bio)pharmaceutical, agrochemical

[< Table of contents](#)



5.48 Synaffix

Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class, clinical-stage antibody-drug conjugate (ADC) technology platform.

As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure.

We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.

Our antibody conjugation technology, GlycoConnect™, enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. Combined with our payload-enhancing linker technology, HydraSpace™, and the superior stability and efficacy offered by our proprietary BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability. Most recently, our underlying platform has been expanded with the addition of the toxSYN™ ADC payload platform that our collaborators may use to build proprietary ADCs for their pipelines.

First-in-human studies of an ADC prepared with Synaffix technology were initiated end of 2018 and are currently ongoing.

Services and Products

What services does your company offer?

- Antibody conjugation technology
- Linker technology
- Cytotoxic payloads

Expertise or Knowledge

- Antibody conjugation
- Preclinical development of ADCs
- Click chemistry



Address

Pivot Park
Kloosterstraat 9
5349 AB Oss



Telephone

+31 (0)88 022 45 05



E-mail

info@synaffix.com



Website

www.synaffix.com



Number of persons employed

14

Area of activity

- Drug development
 - Medical technology

Drug Discovery and Development activities pursued

- Pre-clinical development DMPK
- Pre-clinical development Safety and toxicology
- Clinical development phase I/II

Area of work (indications)

Oncology

[< Table of contents](#)



Synthon is an international pharmaceutical company, and a leader in the field of generic human medicines.

Founded in 1991, Synthon works to develop therapies that address the needs of people worldwide and help improve their health and well-being. With our portfolio of medicines, we provide treatment options for patients in selected therapeutic areas with high unmet medical needs. Through the provision of high-quality generic medicines, we make treatments more affordable and increase access to important remedies. Currently, our products are approved by regulatory agencies in more than 90 countries and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon’s head office is based in Nijmegen, the Netherlands, and the company has affiliates in eight other countries. In 2017, it recorded a turnover of EUR 240 million. The company employs around 1,900 staff of whom over 100 work in Nijmegen.

Services and Products
What services does your company offer?

- Complex small-molecule generics and hybrids form the backbone of our product portfolio.

Expertise or Knowledge
Synthon’s strategy from its inception included the development of a vertically integrated organization for small-molecule generics, controlling every facet of the development chain beginning with research, development and production of active pharmaceutical ingredients through to manufacture and sale of our drug products. Our pipeline is well-filled with research projects and pending regulatory applications

Address
Microweg 22
6545 CM Nijmegen

Telephone
+31 (0)24 372 77 00

E-mail
info@synthon.com

Website
www.synthon.com

Number of persons employed
>100 (around 1,900 worldwide)

Area of activity

- Product development
 - Generic human medicines

Area of work (indications)
We address a variety of therapeutic areas, including allergy, anti-infective, cardiovascular, CNS, oncology, musculoskeletal, systemic and urology



TropiQ Health Sciences operates a technology platform for the discovery and development of molecules to combat insect-borne infectious diseases. TropiQ combines world-class parasitological and entomological expertise with state of the art drug discovery technologies. Through this combination, TropiQ is uniquely positioned to accelerate the development of novel medicines, vaccines and vector control measures.

Services and Products
What services does your company offer?

- Drug screening against pathogens and vectors
- Project management

What products does your company make?

- Research reagents (reference microorganisms, monoclonal antibodies)

Expertise or Knowledge

- Tropical infectious diseases (emphasis on malaria, dengue, tuberculosis)
- Molecular pharmacology
- Entomology
- Assay development and drug discovery

Address
Novio Tech Campus
Transistorweg 5-C02
6534 AT Nijmegen

Telephone
+31 (0)24 366 64 78

E-mail
info@tropiq.nl

Website
www.tropiq.nl

Number of persons employed
10 - 25

Area of activity

- Contract Research Organisation

Drug Discovery and Development activities pursued

- Target selection and validation
- Hit identification
- Lead finding
- Biomarkers / Translational Sciences
- Pre-clinical development DMPK

Area of work (indications)
Tropical infectious diseases

5.51 Vaxxinova



In a fast-changing world, with continuing disease pressure and continuous risk of fast emerging diseases, Vaxxinova is committed to providing adequate preventive solutions. Microorganisms do not respect borders and can spread fast, both across geographical borders and across species.

Vaxxinova believes in ‘business without borders’. In other words, we believe that long term local and global professional partnerships between Vaxxinova and veterinarians, animal health professionals and research institutes are the best way to prevent diseases, reduce the use of antibiotics and support performance improvement programs.

The development of vaccines is crucial for our society as vaccines support disease prevention. They make a positive contribution to ‘One Health’, the collaborative effort of multiple disciplines to attain optimal health for people, animals and the environment. Vaccines also help to make the food production more resource efficient and they support the antibiotics reduction.

Address
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

Telephone
+31 (0)24 204 86 00

E-mail
info@vaxxinova.com

Website
www.vaxxinova.com

Area of activity

- Product development
 - Drug development
 - Diagnostics

Area of work (indications)
Animal health, vaccines

5.52 Xenikos



Xenikos aims to develop new medicines, based on the action of toxin-conjugated antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Expertise or Knowledge

- Development of therapeutic antibodies towards registration in the US and EU

Address
Molenveldlaan 168
6523 RN Nijmegen

Telephone
+31 (0)24 300 01 00

E-mail
info@xenikos.com

Website
www.xenikos.com

Number of persons employed
6 - 10

Area of activity

- Product development
 - Drug development


Drug Discovery and Development activities pursued


- Biomarkers / Translational Sciences
- Pre-clinical development DMPK
- Pre-clinical development Safety and toxicology
- Clinical development phase I/II
- Clinical development phase III/Registration
- Regulatory
- Commercial and marketing

Area of work (indications)
Immune indications

5.53 Miscellaneous Companies


Absano

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Website**
www.absano.com

Alveron Pharma

 **Address**
Novio Tech Campus
Transistorweg 5R
5434 AT Nijmegen


 **Website**
www.alveron.com


Amphera

 **Address**
Onderwijsboulevard 225
5223 DE 's-Hertogenbosch


 **Website**
www.amphera.nl


AMRIF

 **Address**
AgroBusiness Park 10
6708 PW Wageningen


 **Website**
www.amrif.eu


APO-T


 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Website**
www.apo-t.nl


Atro Medical


 **Address**
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss


 **Website**
www.atromedical.com


BIOLEGIO

 **Address**
Lagelandseweg 56
6545 CG Nijmegen


 **Website**
www.biolegio.com


Chardon Pharma

 **Address**
Berhemseweg 8
5373 KH Herpen

 **Website**
www.chardonpharma.com

Charles River

 **Address**
Hambakenwetering 7
5231 DD 's-Hertogenbosch


 **Website**
www.criver.com


Chiralix

 **Address**
Kerkenbos 1013
6546 BB Nijmegen


 **Website**
www.chiralix.com


Citryll

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Website**
citryll.com

Cytura Therapeutics

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss


 **Website**
www.cyturatherapeutics.com


Eurofins Bactimm

 **Address**
Middenkampweg 19
6545 CH Nijmegen


 **Website**
www.eurofins.nl


Escalier Biosciences

 **Address**
Novio Tech Campus
Transistorweg 5 J
6534 AT Nijmegen


 **Website**
www.escalierbio.com


Immunovo

 **Address**
Onderwijsboulevard 219
5223 DE 's-Hertogenbosch

 **Website**
www.immunovo.com

InnatOss Laboratories

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

 **Website**
www.innatoss.com

InterNA Technologies B.V.

 **Address**
Novio Tech Campus
Jonkerbosplein 52
6534 AB Nijmegen


 **Website**
www.interna-technologies.com


LINICAL Benelux


 **Address**
Wanraaij 4
6673 DN Andelst

 **Website**
www.linical.com


MSD Oss


Pharmaceutical Operations
 **Location Moleneind**
Address
Molenstraat 110
5342 CC Oss

Biotech Operations
 **Location De Geer**
Address
Veersemeer 4
5347 JN Oss


 **Website**
www.msd.nl/oss


Netherlands Translational Research Center

 **Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss


 **Website**
www.ntrc.nl


Neurophoxia

 **Address**
Onderwijsboulevard 219
5223 DE 's-Hertogenbosch


 **Website**
www.neurophoxia.com


NeuroDrug Research B.V.

 **Address**
Mercator III,
Toernooiveld 1
6525 ED Nijmegen

 **Website**
www.neurodrugresearch.com

NTRC

 **Address**
Pivot park
Kloosterstraat 9
5349 AB Oss


 **Website**
www.ntrc.nl


OCS Life Sciences

 **Address**
Ruwekampweg 2G
5222 AT 's-Hertogenbosch


 **Website**
ocs-consulting.nl/
ocs-life-sciences/


Okklo Life Sciences

 **Address**
Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen


 **Website**
www.okklo.com


ORCA Therapeutics

 **Address**
FiftyTwoDegrees
Jonkerbosplein 52
6534 AB Nijmegen


 **Website**
www.orca-therapeutics.nl


Pam Gene

 **Address**
P.O. Box 1345
5200 BJ 's-Hertogenbosch


 **Website**
www.pamgene.com


Precision Medicine lab

**Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

**Website**
www.labprecisionmedicinelab.nl

Prexton Therapeutics

**Address**
Pivot Park
Kloosterstraat 9
5349 AB Oss

**Website**
www.prextontherapeutics.com

Staten Biotechnology


**Address**
Novio Tech Campus
Transistorweg 5J
6534 AT Nijmegen

**Website**
www.statenbiotech.com


6.1 Bernhoven




Bernhoven is a general hospital in the Oss-Uden-Veghel region where safety and quality are paramount. Providing the very best care together in a contemporary way, that is what Bernhoven stands for. We achieve this with 150 medical specialists and around 2,100 employees. Bernhoven wants to be the most people-oriented hospital in the Netherlands, where both patients and employees are central. Our expertise, our hospitality and the unique location of our main location, with De Maashorst nature area as the backdrop, form the pillars of this ambition.

 **Address**
Nistelrodeseweg 10
5406 PT Uden

Gezondheidslaan 1a
5342 JW Oss


 **Telephone**
+31 (0)485 84 50 00


 **Website**
www.bernhoven.nl


6.2 Canisius Wilhelmina Ziekenhuis



CWZ is one of the 27 top clinical training hospitals in the Netherlands. Our hospital has 28 medical specialties, 8 paramedical departments, and 5 departments such as emergency care and IC. Almost 4,000 employees and many volunteers provide personal care to patients every day. nature area as the backdrop, form the pillars of this ambition.

 **Address**
Weg door Jonkerbos 100
6532 SZ Nijmegen

 **Telephone**
+31 (0)24 365 76 57

 **E-mail**
klantenservice@cwz.nl


 **Website**
www.cwz.nl


6.3 Jeroen Bosch Ziekenhuis




Our starting point is that patients deserve the best possible care that suits them, offered close by and according to their needs. Together we determine what care they need and from whom.

We use all our of expertises to meet the personal and medical needs and seek cooperation, for example with family and friends, the general practitioner, the municipality and home care. That is what we stand for as Jeroen Bosch Hospital.

 **Address**
Henri Dunantstraat 1
5223 GZ 's-Hertogenbosch

 **Telephone**
+31 (0)73 553 20 00

 **Website**
www.jeroenboschziekenhuis.nl





6.4 Sint Maartenskliniek

At the Sint Maartenskliniek everything revolves around the human movement. As a specialized hospital, we are a leader in the treatment of postural and movement disorders in the Netherlands and Europe.

The Sint Maartenskliniek offers its treatments and care at various locations in the Netherlands: Nijmegen, Woerden, Boxmeer, Panningen and Geldrop.

The Sint Maartenkliniek is known for its approach concerning complex disorders. We focus on the treatment of all orthopedic disorders, rheumatic diseases and rehabilitation after illness or an accident.

 **Address**
Hengstdal 3
6574 NA Ubbergen

 **Telephone**
+31 (0)24 365 99 11

 **E-mail**
contact@maartenskliniek.nl

 **Website**
www.maartenskliniek.nl

Maasziekenhuis Pantein offers specialist medical services in the field of health and well-being. The main target group is the inhabitants of the Land van Cuijk and Noord-Limburg.

In order to be able to offer the best possible care as a hospital close to home, various specialties from the Radboudumc and the Sint Maartenskliniek are also housed in the Maasziekenhuis. As a result, the client has to travel less far and is assured of both the best possible basic care and excellent specialist care.

**Address**
Dokter Kopstraat 1
5835 DV Beugen

**Telephone**
+31 (0)485 84 50 00

**Website**
www.maasziekenhuispantein.nl

Radboud university medical center is a leading academic centre for medical science, education and health care. Knowledge forms the heart of our organisation, connecting research, education and patient care. Over 9.000 staff and 3.000 students are committed and ambitious to contribute to the future of healthcare and medical science. You'll find our main research themes below.

Research institutes and themes

Radboud institute for **Health Sciences**

Cancer development and immune defense

Rare cancers

Tumors of the digestive tract

Urological cancers

Women's cancers

Healthcare improvement science

Infectious diseases and global health

Inflammatory diseases

Mitochondrial diseases

Reconstructive and regenerative medicine

Renal disorders

Vascular damage

Nanomedicine

Radboud institute for **Molecular Life Sciences**

Donders Center for **Medical Neuroscience**


Alzheimer's disease


Disorders of movement


Neurodevelopmental disorders

Sensory disorders

Stress-related disorders

**Address**
Geert Grooteplein Zuid 10
6525 GA Nijmegen

**Telephone**
+31 (0)24 361 11 11

**Website**
www.radboudumc.nl/en/research


< Table of contents


6.7 Rijnstate



Rijnstate is a hospital in the Arnhem, Rheden and De Liemers region. We offer excellent hospital care of top clinical quality. We do this at four locations: Arnhem, Zevenaar, Velp and Arnhem-Zuid.

We are constantly improving our care and expertise. We do a lot of research into the causes of diseases and into better treatments. In addition, we work intensively with patients and with other healthcare providers, inside and outside the hospital, to improve our care.

 **Address**
Wagnerlaan 55
6815 AD Arnhem


 **Telephone**
+31 (0)88 055 88 88


 **Website**
www.rijnstate.nl



6.8 VieCuri Medisch Centrum

VieCuri Medical Center is a top clinical hospital, affiliated with the Cooperating Top Clinical Training Hospitals (STZ). People from the region can go to VieCuri with almost any care demand, both in Venlo and in Venray. In addition, there are regional outpatient clinics in Panningen, Reuver and Horst.


 **Address**
Merseloseweg 130
5801 CE Venray


 **Telephone**
+31 (0)478 52 22 22


 **Website**
www.viecuri.nl



Gelderse Vallei Hospital in Ede provides medical care, research and innovation. We provide patients with tools that they can use to develop a healthy lifestyle to generate health benefits for their future lives.

 **Address**
Willy Brandtlaan 10
6716 RP Ede

 **Telephone**
+31 (0)318 43 43 43

 **Website**
www.geldersevallei.nl/home

